

# National ADAP Monitoring Project Annual Report

May 2010





# National ADAP Monitoring Project Annual Report

*Prepared by*

National Alliance of State and Territorial AIDS Directors (NASTAD)

Beth Crutsinger-Perry

Murray C. Penner

Britten Pund

May 2010



## Acknowledgements

The National Alliance of State and Territorial AIDS Directors (NASTAD) thanks state ADAP and AIDS program managers and staff for their time and effort in completing the National ADAP Survey which serves as the foundation for this report, and for providing ongoing updates to inform the National ADAP Monitoring Project. NASTAD also would like to thank Lanny Cross and Dr. Paul Arons, consultants, for their valuable contributions to NASTAD's ADAP Monitoring and Technical Assistance Program.

The National ADAP Monitoring Project is one component of NASTAD's National ADAP Monitoring and Technical Assistance Program which provides ongoing technical assistance to all state and territorial ADAPs. The program also serves as a resource center, providing timely information on the status of ADAPs, particularly those experiencing resource constraints or other challenges, to national coalitions and organizations, policy makers, industry members, and state and federal government agencies. NASTAD received support for the National ADAP Monitoring and Technical Assistance Program in 2009 from the following companies: Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline and Tibotec Therapeutics. NASTAD also receives funding to provide technical assistance to ADAPs through a Training and Technical Assistance Cooperative Agreement with the Health Resources and Services Administration (HRSA).

## Table of Contents



Executive Summary ..... 1

Detailed Findings ..... 5

ADAP Clients and Eligibility Criteria ..... 7

ADAP Budget ..... 8

ADAP Drug Expenditures, Prescriptions, and Formularies ..... 9

Insurance Coverage ..... 10

ADAP Cost-containment Measures/Management Policies and Waiting Lists ..... 11

Summary Table I ..... 13

Summary Table II: Total Clients Enrolled/Served, Drug Expenditures,  
and Prescriptions Filled, June 2008 and June 2009 ..... 14

Summary Table III: Total Clients Enrolled/Served and Program Expenditures, FY2008 ..... 15

Charts ..... 17

Chart 1: ADAP Client Enrollment, June 2003 – 2009 ..... 18

Chart 2: ADAP Clients Enrolled and Top Ten States, by Clients Enrolled, FY2008 ..... 18

Chart 3: ADAP Client Utilization, June 1996 – 2009 ..... 19

Chart 4: ADAP Clients Served and Top Ten States, by Clients Served, June 2009 ..... 19

Chart 5: Trends in ADAP Client Utilization, June 1996 – 2009 ..... 20

Chart 6: ADAP Clients Served, by Race/Ethnicity, June 2009 ..... 20

Chart 7: ADAP Clients Served, by Gender, June 2009 ..... 21

Chart 8: ADAP Clients Served, by Age, June 2009 ..... 21

Chart 9: ADAP Clients Served, by Income Level, June 2009 ..... 22

Chart 10: ADAP Clients Served, by Insurance Status, June 2009 ..... 22

Chart 11: ADAP Clients by CD4 Count, Enrolled During 12-Month Period, June 2009 ..... 23

Chart 12: The National ADAP Budget, FY1996 – 2009 ..... 23

Chart 13: The National ADAP Budget, by Source, FY1996 – 2009 ..... 24

Chart 14: The National ADAP Budget, by Source, FY2009 ..... 24

Chart 15: Number of ADAPs, by Budget Source, FY2009 ..... 25

Chart 16: Number of ADAPs with Funding Decreases, by Budget Source, FY2008 – 2009 ..... 25

Chart 17: Part B ADAP Earmark, FY1996 – 2009 ..... 26

Chart 18: Part B ADAP Supplemental Funding, FY2001 – 2009 ..... 26

Chart 19: Part B Base Contribution Directed to ADAP, FY1996 – 2009 ..... 27

Chart 20: Part A Contribution Directed to ADAP, FY1996 – 2009 ..... 27

Chart 21: State Funding, FY1996 – 2009 ..... 28

Chart 22: Drug Rebates, FY1996 – 2009 ..... 28

Chart 23: Cost Recovery and Other Cost-Saving Mechanisms (Excluding Drug Rebates), FY2009 ..... 29

Chart 24: Percent Change in ADAP Drug Expenditures, June 1996 – 2009 ..... 29

Chart 25: ADAP Drug Expenditures and Top 10 States, by Drug Expenditures, June 2009 ..... 30

Chart 26: ADAP Per Capita Drug Expenditures, June 1996 – 2009 ..... 30

Chart 27a: ADAP Drug Expenditures (Including Drug Purchases and Co-Payments), June 2009 ..... 31

Chart 27b: ADAP Prescriptions Filled (Including Drug Purchases and Co-Payments), June 2009 ..... 31

Chart 28: ADAPs Paying Co-Payments on Behalf of Clients, June 2009 ..... 32

Chart 29: ADAP Drug Expenditures, by Drug Class, June 2009 ..... 32

Chart 30:	ADAP Prescriptions Filled, by Drug Class, June 2009 . . . . .	33
Chart 31:	ADAP Drug Purchasing Mechanisms, June 2009 . . . . .	33
Chart 32a:	Clients Served in Insurance Purchasing/Maintenance Programs, June 2002–2009 . . . . .	34
Chart 32b:	Estimated ADAP Spending on Insurance Purchasing/Maintenance Programs, FY2002–2009 . . . . .	34
Chart 33:	ADAP Income Eligibility, June 30, 2009 . . . . .	35
Chart 34:	ADAP Enrollment Processes, June 2009 . . . . .	35
Chart 35:	ADAP Policies Related to Medicare Part D, June 2009 . . . . .	36
Chart 36:	Number of States with ADAP Waiting Lists, by Survey Period, July 2002–March 2010 . . . . .	36
Chart 37:	Number of People on ADAP Waiting Lists, by Survey Period, July 2002–March 2010 . . . . .	37
Chart 38:	ADAP Formulary Coverage of Antiretroviral Drugs (ARVs), June 30, 2009 . . . . .	37
Chart 39:	ADAP Formulary Coverage of Drugs Recommended (“A1”) for Prevention and Treatment of Opportunistic Infections (OIs), June 30, 2009 . . . . .	38

## Tables . . . . . 39

Table I:	ADAP Clients Served, by Race/Ethnicity June 2009 . . . . .	40
Table II:	ADAP Clients Served, by Gender, June 2009 . . . . .	41
Table III:	ADAP Clients Served, by Age, June 2009 . . . . .	42
Table IV:	ADAP Clients Served, by Income Level, June 2009 . . . . .	43
Table V:	ADAP Clients Served, by Insurance Status, June 2009 . . . . .	44
Table VI:	ADAP Clients by CD4 Count, Enrolled During 12-Month Period, June 2009 . . . . .	45
Table VII:	The National ADAP Budget, by Source, FY 2009 . . . . .	46
Table VIII:	The ADAP Budget, FY 2007 and FY 2009 . . . . .	49
Table IX:	Major FY 2009 Budget Categories Compared with FY 2008 . . . . .	50
Table X:	Cost Recovery and Other Cost-Saving Mechanisms (Excluding Drug Rebates), FY 2009 . . . . .	52
Table XI:	ADAP Drug Expenditures (Including Drug Purchases and Co-Payments), June 2009 . . . . .	53
Table XII:	ADAP Prescriptions Filled (Including Drug Purchases and Co-Payments), June 2009 . . . . .	54
Table XIII:	ADAP Drug Expenditures, by Drug Class, June 2009 . . . . .	55
Table XIV:	ADAP Prescriptions Filled, by Drug Class, June 2009 . . . . .	56
Table XV:	Federal ADAP Funds Used For Number of Clients Served Through Insurance Purchasing/Maintenance, 2009 . . . . .	57
Table XVI:	ADAP Client Eligibility Requirements, June 30, 2009 . . . . .	58
Table XVII:	ADAP Client Enrollment Processes, June 2009 . . . . .	59
Table XVIII:	ADAP Management Policies in Place, June 30, 2009 . . . . .	60
Table XIX:	ADAP Policies Related to Medicare Part D, June 2009 . . . . .	62
Table XX:	Number of People on ADAP Waiting Lists, by Survey Period, July 2002-March 2010 . . . . .	63
Table XXI:	ADAP Formulary Coverage, December 31, 2009 . . . . .	66
Table XXII:	HIV/AIDS Medications . . . . .	67
Table XXIII:	Patient Assistance Program Eligibility by Company, April 2010 . . . . .	68

## Glossary . . . . . 69

## References . . . . . 73

## Executive Summary



The *Annual Report* of NASTAD's National ADAP Monitoring Project is based on a comprehensive survey of all AIDS Drug Assistance Programs (ADAPs). This 15<sup>th</sup> release of the *Annual Report* updates prior findings with data from ADAP's fiscal years 2008 and 2009<sup>1</sup> as well as provides a detailed snapshot of data from the month of June 2009. This *Annual Report* reflects the latest available data and discusses recent policy and programmatic changes affecting ADAPs.

ADAPs provide life-saving HIV treatments to low income, uninsured, and underinsured individuals living with HIV/AIDS in all 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the U.S. Virgin Islands, American Samoa, the Federated States of Micronesia, Guam, the Northern Mariana Islands, and the Republic of the Marshall Islands. In addition, some ADAPs provide insurance continuation and Medicare Part D wrap-around services to eligible individuals. ADAPs are a component of the federal Ryan White Part B program that provides necessary medical and support services to low income, uninsured, and underinsured individuals living with HIV/AIDS in all states, territories and associated jurisdictions.

### ADAP Client Enrollment and Utilization

In FY2008, ADAP client enrollment increased by an unprecedented average of 1,554 new clients per month. Between June 2008 and June 2009 ADAP client enrollment increased 17,507; this is the largest increase since ADAP client enrollment data began being collected in 2003. The greatest previous increase was 7,728 individuals between June 2005 and June 2006. In June 2009, ADAPs provided medications to 125,479 individuals, a fourteen percent (14%) increase in client utilization over June 2008 and the largest increase since 1998-1999. ADAPs typically have more individuals enrolled in a given month than are served; in June 2009, ADAPs provided medications to seventy-four percent (74%) of the 168,707 enrolled individuals (a two percent increase of utilization vs. enrollment over the previous year).

While these increases likely result in important health outcomes for people living with HIV/AIDS, they also lead to considerable fiscal stress for many ADAPs unable to keep up with client demand and the increasing program costs. And, as a result of the nation's economic crisis, more Americans living with HIV are relying on

public health safety net programs, like ADAP, as a vital resource for medications. These factors, among others, have resulted in a myriad of cost containment measures for ADAPs, including waiting lists totaling 929 individuals in nine states (as of April 22, 2010).

### ADAP Budget

In FY2009, the national ADAP budget climbed to \$1.59 billion, a four percent (4%) increase from FY2008. In spite of this increase, state funding contributions directed to ADAP decreased by 34 percent. This marks the lowest state funding contribution to ADAPs since 2003 and exemplifies the severity of state fiscal crises nationwide. The federal appropriation in FY2009 to ADAP increased by \$20.6 million from FY2008 (however, due to various distribution provisions such as unobligated balances and hold harmless within the Ryan White Program, ADAP grants to states increased only slightly (\$5.6 million) in FY2009). ADAP earmark funding to states comprised less than half (49%) of the total ADAP budget in FY2009; the earmark has been declining as a share of the total budget since 2000 when it peaked at 68 percent of the total. The last time the federal ADAP earmark represented less than 50 percent of the national ADAP budget was in FY1997 when it comprised 40 percent. In order to fill the gaps resulting from significantly decreased state funding and nearly stagnant federal ADAP earmark funding, ADAPs relied more heavily on rebates and discounts from pharmaceutical manufacturers to maintain their programs.

### ADAP Coordination with Other Payers

ADAPs continue to increase their efficiency in coordination with a variety of public and private payers. Capitalizing on the payer of last resort requirement in the Ryan White Program, ADAPs reported significant increases in cost recovery from Medicaid and other benefit providers. In addition to rebates received in FY2009, \$55.9 million was recovered and added back into ADAP budgets, more than double the amount reported in FY2008.

ADAPs have also invested heavily in health insurance purchasing and maintenance, which is cost effective for the programs and provides comprehensive health benefits to clients, rather than strictly medications. Forty-three ADAPs purchase and/or maintain

insurance for clients through private insurers, state high-risk insurance pools, COBRA, etc. The extent to which state ADAPs can purchase or maintain insurance coverage for people with HIV/AIDS depends on state and federal insurance law and reform; state ADAPs capacity to develop and manage such programs; and the availability of resources for this purchase. ADAPs anticipate expending \$161.8 million (ten percent of the national ADAP budget) in FY2009 purchasing and/or maintaining individuals health insurance; this estimate represents a 52 percent increase over FY2008. Client utilization in June 2009 grew 98 percent compared to June 2008. Greater access to insurance services provides comprehensive health coverage to a larger number of individuals at a lower cost than traditional ADAP services. ADAP per capita expenditures for drug purchases averaged \$1,003 per month in June 2009 while ADAP per capita expenditures for insurance purchasing/maintenance averaged \$331 per month in June 2009.

### Looking Ahead

ADAPs are currently situated in the eye of the “perfect storm:” minimal increases in federal appropriations, significant state budget cuts, increased program demand due to unemployment, heightened national efforts on HIV testing and linkages into care, and new HIV Treatment Guidelines calling for earlier therapeutic treatments. These collective stressors are all contributing to a fiscal “tipping point” for ADAPs from which recovery will be difficult.

Health reform, though a viable solution to some fiscal and access to care concerns, will not bring immediate relief to ADAPs. Some portions of reform that will impact ADAPs specifically are:

- Medicaid eligibility expansion,
- Increase in individuals covered by insurance plans;
- ADAP’s wrap-around Medicare Part D expenditures counting toward True Out Of Pocket (TrOOP) expenditures;
- Narrowing and closing the Medicare Part D doughnut hole,
- An increase in the Medicaid rebate amount for purchased drugs, and
- 340B pricing transparency.

These changes will bring both comprehensive care for ADAP clients and fiscal relief for the programs; however implementing health reform provisions will also require ADAPs to build the infrastructure necessary to make these changes. Last year, the Ryan White Program was reauthorized for four years, until September 2013. The next reauthorization of the program may bring additional changes to ADAPs and other Ryan White grantees.

The current national and state fiscal crises and their impact on ADAP will continue to be a challenge for programs. Addressing the issues currently facing ADAPs requires federal, state, and pharmaceutical partnership. The federal government must contribute more funding to ADAPs through appropriations. State governments must maintain, restore, and increase resources for ADAPs. Pharmaceutical partners must augment current agreements to create a “bridge” for ADAPs to realize the benefits of provisions in health reform.<sup>2</sup> This integrated approach, coupled with continuing ADAP program efficiency, is required in order for ADAPs to continue to provide life-saving treatments for individuals living with HIV/AIDS.

## Detailed Findings



A comprehensive survey was sent to all 58 jurisdictions that received federal ADAP earmark funding in FY2009; 52 responded (see Methodology). Budget data are from FY2009 and most other data is from FY2008<sup>1</sup> and June 2009, unless otherwise noted. The detailed findings of the survey findings are included below.

## ADAP CLIENTS AND ELIGIBILITY CRITERIA

### ADAP Clients

ADAP client enrollment and client utilization were at their highest levels in FY2009. ADAPs primarily serve low-income, uninsured clients, most of whom are minorities. Client demographics have remained fairly constant over time, although there are significant variations by state and region.

- During FY2008, 200,673 clients were enrolled in ADAPs nationwide, including 39,437 new clients enrolled throughout the year. Client enrollment ranged from four in Guam to 39,305 in California in FY2008. Typically, fewer clients are served in ADAPs than are enrolled at any given time—ADAPs served 177,410 clients in FY2008 (see Summary Table III).
- ADAPs provided medications to 125,479 clients across the country in June 2009. ADAPs also paid for insurance coverage (premiums, co-payments, and/or deductibles) for 30,621 clients, some of whom may have also received medications (see Charts 3, 4, and 32 and Table XV) in that month. The number of clients receiving prescription medications has grown significantly since 1996 (254% among the 49 ADAPs reporting data in both periods) (see Charts 5 and 24). Client utilization increased by 14% between June 2008 and June 2009.
- Mirroring the national epidemic, most ADAP clients are concentrated in states with the highest numbers of people living with HIV. Ten states accounted for 67% of total enrollment in FY2008; five states accounted for 50% (California, New York, Florida, Texas, and New Jersey) (see Chart 2). The distribution is similar for clients served in June 2009 (see Chart 4).
- In June 2009, client demographics were as follows (see Charts 6-11 and Tables I-VI):
  - African Americans and Hispanics represented

57% (31% and 26%, respectively) of clients served. Combined, Asians, Native Hawaiian/Pacific Islanders, and Alaskan Native/American Indians represented approximately two percent of the total ADAP population. Non-Hispanic whites comprised 35%.

- More than three-quarters (77%) of ADAP clients were men.
- Half of clients (47%) were between the ages of 45 and 64. Individuals on ADAP rolls ranging in age from 45-64 has increased 9% since June 2004. ADAP demographics follow the national trend for individuals living with HIV to live longer.
- Three-quarters (77%) were at or below 200% of the Federal Poverty Level (FPL). In 2009, the FPL was \$10,830 annually (slightly higher in Alaska and Hawaii) for a family of one.
- A majority of ADAP clients (67%) were uninsured. Twenty-one percent had private insurance, 12% Medicare, 9% Medicaid, and eight percent were dual beneficiaries of both Medicaid and Medicare. For those with other sources of coverage, ADAP wraps around, such as paying client cost-sharing requirements (e.g., premiums, deductibles, co-payments) and/or providing additional medications for those clients who may be subject to monthly or annual prescription drug limits under other forms of coverage.
- CD4 count information of clients was available from 34 ADAPs and reflects clients enrolled in ADAPs over the last 12 months or the most recent 12 months for which data are available. Almost half of ADAP clients (48%) had CD4 counts of 350 or below (at time of enrollment or at recertification), one potential indication of more advanced HIV disease. Higher CD4 counts may represent successful treatment or early intervention efforts.

### ADAP Eligibility Criteria


Ryan White requires all ADAP clients to be HIV-positive as well as low-income and uninsured or underinsured, but each ADAP determines its own income eligibility criteria, both by balancing between a goal of targeting those who may not qualify for other low-income programs, such as Medicaid, and by seeing how far their budgets can go in a given year. As a result of these factors, eligibility criteria vary by state, although some

ADAPs set their eligibility criteria to be consistent with other health programs within their state (see Chart 33 and Table XVI).

- All ADAPs require that individuals provide clinical documentation of HIV infection. Eight ADAPs reported additional clinical eligibility criteria (e.g., specific CD4 or viral load ranges).
- ADAP income eligibility in June 2009 ranged from 200% FPL in 10 states to 500% FPL in seven. Overall, 24 states set income eligibility at greater than 300% FPL. Eighteen states were between 201% and 300% FPL. In addition to using income to determine eligibility, 14 ADAPs reported having asset limits in place in June 2009.
- All ADAPs require enrollees to be residents of the state in which they are seeking medications. Many ADAPs require documentation of residency and a few have specific residency requirements (e.g., must be a resident for 30 days).

## ADAP BUDGET

The ADAP budget reached \$1.59 billion in FY2009, an increase of approximately \$70 million (5%) over FY2008.<sup>3</sup> Since FY1996, the budget has grown nearly eight-fold. Many funding streams increased over the last year, however states experienced a drastic decrease in FY2009 state contributions (a decrease of 34% over FY2008). While the ADAP earmark continues to represent the largest share of the budget, it no longer drives budget growth, as it did early on in the program’s history (see Charts 12-23 and Tables VII-X).



- In FY2009, the ADAP earmark was \$779.8 million. The earmark was one-quarter of the budget in FY1996, the year it was created, rose to more than two-thirds (68%) of the budget in FY2000, and has more recently declined as a share of the budget, to 49% in FY2009.
- State funding accounted for \$215.3 million, or 14% of the ADAP budget in FY2009, a decrease of 34% over FY2008.
- In FY2009, manufacturer rebates reached their highest amount and percent of the national ADAP budget in the programs history. Drug rebates accounted for \$497.6 million, or 31%, of the national ADAP budget in FY2009. Rebates represent an increasingly critical component of the ADAP budget, and drove overall budget growth over the period, accounting for more than 50% of growth between FY2008 and FY2009. Drug rebates have risen from six percent of the budget in FY1996 to 31% in FY2009. ADAPs must actively seek drug rebates and, while not all ADAPs do so (because of varying state drug purchasing mechanisms), drug rebates accounted for a quarter or more of the ADAP budget in 20 states.
- ADAP Supplemental Drug Treatment Grants (21 in FY2009) accounted for three percent (\$41.5 million) of the overall ADAP budget, and increased by less than \$2 million between FY2008 and FY2009 following a four-fold increase between FY2006 and FY2007. This minimal increase resulted in smaller awards of ADAP Supplemental to all states due to an increase in the number of states eligible for and awarded ADAP Supplemental funding. In FY2010, it is expected that more states will be eligible for ADAP Supplemental funding, decreasing the appropriation to individual states even further. ADAP Supplemental Drug Treatment Grants are a five percent set-aside from the ADAP earmark and represent a portion of the overall federal contribution.
- Allocations to ADAP from the Part B “base” accounted for two percent (\$27.6 million) of the budget in FY2009.
- Allocations to ADAP from the Part B “base” supplemental funding accounted for one percent

(\$10 million) of the budget in FY2009 (this was a new funding source in FY2009).

- Allocations to ADAP from Part A funding represented \$13.3 million or one percent of the ADAP budget in FY2009; ten metropolitan jurisdictions directed funding to ADAPs in FY2009.
- ADAP budget composition also varies by state. The earmark is provided to all eligible jurisdictions (58 in FY2009) based on a formula of living HIV (non-AIDS) and AIDS cases. The remaining funds are either awarded on a competitive basis or allocated as a result of a demonstrated need. The breakdown of other sources of funding across the country was as follows (among 53 ADAPs reporting data) (see Chart 15 and Table VII):
  - Part B ADAP Supplemental Treatment Grants: 21 ADAPs were eligible for and received funding;
  - Part B Base Funds: 23 ADAPs received funding, 30 did not;
  - State General Revenue Support: 36 ADAPs received funding, 17 did not;
  - Part A Funds: 10 ADAPs received funding, 43 did not;
  - Other State/Federal Funds: 8 received funding, 45 did not;
  - Drug Rebates: 39 ADAPs received funding, 15 did not.
- While most ADAPs had increases in their budgets between FY2008 and FY2009, some had decreases overall or in specific funding streams (see Chart 16 and Tables VIII and IX):
  - Overall Budget: 36 ADAPs had increases or level funding, 21 had decreases;
  - Part B ADAP Earmark: 47 ADAPs had increases or level funding, 5 had decreases;
  - Part B ADAP Supplemental Drug Treatment Grants: 7 ADAPs had increases, 14 had decreases;
  - Part B Base Funds: 14 ADAPs had increases or level funding, 14 had decreases;
  - State General Revenue Support: 19 ADAPs had increases or level funding, 21 had decreases;
  - Part A Funds: 6 ADAPs had increases or level funding, 5 had decreases;
  - Drug Rebates: 28 ADAPs had increases or level funding, 13 had decreases.

- While not counted as an ADAP budget category in this report (due to its high variability and significant delays in receipt of funds), “cost recovery” for medications purchased through ADAP (other than drug rebates), represented \$55.9 million in FY2009. Private insurance recovery, in which an ADAP receives reimbursement from insurance providers, was the largest component of all cost recovery sources (62%). Cost recovery from Medicaid represented 27% of this funding and other sources, including manufacturers’ free products, represented eleven percent (see Chart 23 and Table X).



## ADAP DRUG EXPENDITURES, PRESCRIPTIONS, AND FORMULARIES

### ADAP Drug Expenditures and Prescriptions

Drug spending and utilization have increased over time. The distribution of drug expenditures and prescriptions varies across the country, reflecting differing formularies and prescribing patterns. Antiretrovirals, the standard of care for HIV, account for the majority of ADAP drug expenditures and prescriptions filled.

- ADAP spending on prescription drugs (directly and indirectly through insurance coverage) totaled \$1.2 billion in FY2008, accounting for almost all (87%) of program expenditures (the remainder was for program administration and other activities) (see Summary Table III).
- ADAP drug expenditures were \$125,838,306 in June 2009, ranging from a low of \$8,090 in Guam to a high of \$32 million in California. Ten states accounted for 75% of all drug spending; five states (California, New York, Texas, New Jersey, and Pennsylvania) accounted for over half (59%) of all drug spending (see Chart 25 and Tables XI).
- Drug spending by ADAPs has increased more than seven-fold (617%) since 1996 (in the same 46 states reporting data in both periods), more than twice the rate of client growth over this same period. It, too, has continued to increase but at slower rates. Between June 2008 and June 2009, drug expenditures grew 15 percent (see Chart 24).

- Average per capita drug expenditures were \$1,003 in June 2009. Estimated annual per client expenditures were \$12,034 (see Chart 26).<sup>4</sup>
- The average expenditure per prescription was \$302. It was significantly higher for antiretrovirals (\$465) than non-antiretrovirals (\$81 for “A1” OIs and \$64 for all other drugs).
- ADAPs filled a total of 416,590 prescriptions in June 2009 (see Chart 27b and Table XII).
- Most ADAP drug spending is on FDA-approved HIV antiretrovirals<sup>5</sup> (91% in June 2009). The 31 “A1” drugs highly recommended for the prevention and treatment of HIV-related opportunistic infections (OIs)<sup>6,7</sup> accounted for two percent of expenditures and eight percent of prescriptions. All other drugs (including medications for depression, hypertension, and diabetes), accounted for seven percent of drug expenditures, but 31% of prescriptions filled (see Charts 29 and 30 and Tables XIII and XIV).



## ADAP Formularies

ADAP formularies differ significantly across the country.



- All ADAPs cover at least one ARV in each of the approved six ARV drug classes, as required under the Ryan White Program.
- ADAPs may cover slightly fewer than the full set of “A1” OIs if they cover equivalent medications, also highly recommended, or have other state-level programs that can provide these medications (see Charts 38 and 39 and Table XXI).
- Hepatitis A, B, and C infections are important considerations for people with HIV, and ADAPs play a unique role in the provision of treatment for the hepatitis C virus (HCV) and vaccines for hepatitis A and B viruses in the U.S.
  - Twenty-seven ADAPs cover hepatitis A and B vaccines, which are recommended for those at high risk for and living with HIV.<sup>8</sup>
  - HCV is classified as an HIV-related opportunistic infection, due to the relatively high co-infection rate of HIV and HCV.<sup>9</sup> Because there is no national funding source specifically for HCV treatment, most of the burden for treating co-infected patients has fallen on ADAPs and other Ryan White programs. In June 2009, 24 ADAPs covered treatment for HCV on their formularies.

## INSURANCE COVERAGE

### Insurance Purchasing/Maintenance Programs

The Ryan White Program allows states to use ADAP earmark dollars to purchase health insurance and pay insurance premiums, co-payments, and/or deductibles for individuals eligible for ADAP, provided the insurance has comparable formulary benefits to that of the ADAP.<sup>8,9</sup> States are increasingly using ADAP funds for this purpose.

- 43 ADAPs used funds for insurance purchasing/maintenance in 2009 representing \$161.8 million in estimated expenditures in FY2009. ADAPs also reported spending over \$145 million on insurance purchasing/maintenance in FY2008.



- In June 2009, 30,621 ADAP clients were served by such arrangements (see Chart 32 and Table XV).
- Spending on insurance represented an estimated \$331 per capita, about two-thirds less than per capita drug expenditures in that month (\$1,003).

### Coordination with Medicare Part D

In calendar year 2009, it is estimated that 16% of ADAP clients were also Medicare-eligible (representing about 17,000 enrolled clients). A subset of these clients were dually eligible for Medicare and Medicaid.

- To meet the federal requirements and maintain appropriate medication coverage for their clients, 53 ADAPs have developed policies to coordinate with the Part D benefit (see Chart 35 and Table XIX). As of June 2009:
  - 25 ADAPs pay Part D premiums;
  - 28 ADAPs pay Part D deductibles;
  - 38 ADAPs pay Part D co-payments for ADAP clients eligible for Part D;

- 35 ADAPs pay for all medications on their ADAP formularies when their Part D clients reach the coverage gap or “doughnut hole.” This action meets the requirement of “payer of last resort” but also provides a safety net for continuing HIV treatment access for beneficiaries since ADAP contributions do not count towards true out-of-pocket (TrOOP) expenditures.

- An increasing number of ADAPs are enrolling clients in State Pharmacy Assistance Programs (SPAPs) whose contributions do count toward TrOOP, helping to move the beneficiary through the coverage gap and into Part D catastrophic coverage. SPAPs may also create cost savings for ADAPs by enabling eligible clients to move off ADAP program rolls. As of June 2009, 17 states had SPAPs into which the ADAP could enroll some or all of their Medicare Part D clients and four additional ADAPs were considering implementing an SPAP for individuals living with HIV to assist them with Medicare Part D costs.<sup>10</sup>

### ADAP COST-CONTAINMENT MEASURES/ MANAGEMENT POLICIES AND WAITING LISTS

Waiting lists are the most visible representation of fiscal crisis for ADAP services, however ADAPs also control costs or manage resource constraints in a variety of ways, including reducing or limiting formularies, establishing enrollment caps on particular drugs, instituting patient cost-sharing on medications when it was previously not required, or limiting the number of prescriptions provided per month. When states have had to implement waiting lists, they generally report working with pharmaceutical manufacturer patient assistance programs (PAPs) to help those on waiting lists access medications where possible. These programs, however, are not meant to be permanent sources of drug access and they require people to apply often, sometimes as frequently as every month, and to each drug manufacturer separately. It is important to note that some of these cost-containment measures are also used by ADAPs to ensure efficient use of funds and support appropriate clinical management of patients on an on-going basis (see Table XVIII).

- Eleven ADAPs, five with current waiting lists, have instituted additional cost-containment measures since April 1, 2009. Eleven ADAPs, including four with current waiting lists, are considering implementing new or additional cost- containment measures by the end of March 2011. Among cost containment measures being considered, reductions in services provided by ADAP, including reducing ADAP formularies and instituting waiting lists, are most apparent. A less visible measure is moving funds from Part B base to supplant gaps in funds in ADAP. These contributions may prevent additional cost-containment measures.
  
- Based on a weekly updated survey conducted by NASTAD, as of April 22, 2010, nine states reported a total of 929 people on waiting lists (see Charts 36 and 37 and Table XX). The number of clients on waiting lists has been slowly growing since September 2007, when no clients were reported on lists.
  
- The size of waiting lists has fluctuated within and across states over time. Based on bi-monthly surveys conducted between July 2002 and March 2010 (45 surveys overall):
  - The highest number of states reporting a waiting list in any given period was 11.
  - 13 ADAPs had waiting lists in 10 or more of the survey periods.
  - The number of people on waiting lists ranged from a low of one to a high of 1,629 (the average was 571). The highest number of individuals on any one state’s waiting list was 891.

## CHARTS AND TABLES

Charts for each major finding and tables, with data provided by state, are included in the full report.

# Summary Table I

State/Territory	Financial Eligibility as % of FPL <sup>1</sup>	Total FY2009 Budget <sup>2</sup>	State Contribution	State Contribution as % of Total Budget	June 2009 Clients Served	June 2009 Drug Expenditures	June 2009 Prescriptions Filled	June 2009 Per Capita Drug Expenditures <sup>3</sup>	June 2009 Insurance Expenditures
Alabama	250% GR	\$13,810,210	\$2,225,000	16%	1,335	\$1,484,333	4,637	\$1,112	\$3,314
Alaska	300% GR	\$696,621	\$0	0%	63	\$88,957	232	\$1,412	\$18,000
American Samoa	--	\$2,803	--	--	--	--	--	--	--
Arizona	300% GR	\$12,624,545	\$1,000,000	8%	1,032	\$1,179,812	4,234	\$1,143	--
Arkansas	200% GR	\$4,459,575	\$0	0%	469	\$417,336	1,786	\$890	\$4,848
California	400% GR	\$412,032,756	\$70,849,000	17%	23,027	\$32,060,460	92,769	\$1,392	\$1,254,458
Colorado	400% GR	\$14,677,087	\$1,357,404	9%	2,257	\$1,006,183	3,472	\$446	\$213,227
Connecticut	400% NET	\$20,256,962	\$606,678	3%	1,439	\$1,806,598	5,073	\$1,255	\$0
Delaware	500% GR	\$3,513,056	\$0	0%	531	\$185,144	2,011	\$349	\$6,649
District of Columbia	500% GR	\$14,429,241	\$0	0%	1,454	\$1,441,644	3,859	\$992	\$46,447
Federated States of Micronesia	--	\$7,475	--	--	--	--	--	--	--
Florida	400% GR	\$93,404,741	\$8,000,000	9%	13,258	\$5,747,226	27,992	\$433	\$131,839
Georgia	300% GR	\$41,532,108	\$10,000,000	24%	3,878	\$3,849,672	11,917	\$993	\$112,500
Guam	200% NET	\$91,055	\$0	--	4	\$8,090	18	\$2,022	--
Hawaii	400% GR	\$3,129,825	\$440,535	14%	227	\$209,464	679	\$923	\$18,625
Idaho	200% GR	\$2,417,362	\$801,300	33%	121	\$216,444	290	\$1,789	--
Illinois	400% GR	\$44,621,331	\$14,504,778	33%	3,865	\$3,628,700	10,056	\$939	\$41,542
Indiana	300% GR	\$17,280,488	\$0	0%	1,462	\$244,966	7,387	\$168	\$299,344
Iowa	200% GR	\$2,355,209	\$526,078	22%	356	\$268,944	936	\$755	\$45,175
Kansas	300% GR	\$6,956,542	\$500,000	7%	486	\$634,242	1,253	\$1,305	\$14,705
Kentucky	300% GR	\$4,782,107	\$0	0%	1,286	\$773,654	3,571	\$602	\$62,691
Louisiana	300% GR	\$19,368,508	\$0	0%	1,934	\$2,038,551	2,488	\$1,054	\$22,529
Maine	500% GR	\$1,051,754	\$50,000	5%	188	\$51,210	600	\$272	\$22,887
Marshall Islands	--	\$2,968	--	--	--	--	--	--	--
Maryland	500% GR	\$42,479,475	\$0	0%	3,081	\$2,444,882	10,156	\$794	\$663,971
Massachusetts	500% GR	\$19,336,587	\$1,893,375	10%	3,877	\$362,229	10,790	\$93	\$815,523
Michigan	450% GR	\$24,902,162	\$682,000	3%	1,860	\$1,904,570	7,526	\$1,024	\$76,549
Minnesota	300% GR	\$13,649,101	\$4,525,577	33%	594	\$318,218	1,243	\$536	\$201,699
Mississippi	--	\$7,610,703	--	--	--	--	--	--	--
Missouri	300% GR	\$14,497,437	\$4,390,000	30%	1,376	\$1,900,096	5,280	\$1,381	\$116,201
Montana	330% GR	\$764,984	\$171,692	22%	61	\$62,583	169	\$1,026	\$2,448
Nebraska	200% GR	\$2,634,876	\$900,000	34%	268	\$182,601	630	\$681	\$16,000
Nevada	400% GR	\$6,856,644	\$0	0%	746	\$674,367	1,885	\$904	\$42,092
New Hampshire	300% GR	\$3,017,239	\$0	0%	209	\$183,018	936	\$876	--
New Jersey	500% GR	\$73,382,041	\$8,600,000	12%	4,826	\$7,322,639	22,576	\$1,517	\$282,201
New Mexico	400% GR	\$2,248,691	\$0	0%	616	\$31,485	98	\$51	\$191,227
New York	406% GR	\$257,158,973	\$3,302,461	1%	14,399	\$22,923,977	68,412	\$1,592	\$1,789,856
North Carolina	300% GR	\$34,616,148	\$10,695,504	31%	3,810	\$3,618,023	14,325	\$950	\$289,894
North Dakota	400% NET	\$395,098	\$0	0%	40	\$42,900	104	\$1,073	--
Northern Mariana Islands	--	\$5,606	--	--	--	--	--	--	--
Ohio	500% GR	\$17,498,398	\$693,100	4%	2,109	\$433,274	6,512	\$205	\$377,943
Oklahoma	200% GR	\$8,877,172	\$1,620,000	18%	884	\$688,236	2,857	\$779	\$117,063
Oregon <sup>4</sup>	200% GR	\$11,849,101	\$1,643,278	14%	1,861	\$217,047	6,273	\$117	\$710,777
Pennsylvania	337% GR	\$69,381,901	\$16,150,699	23%	3,472	\$4,807,876	14,498	\$1,385	\$13,683
Puerto Rico	200% NET	\$27,340,354	\$0	0%	3,836	\$3,014,978	9,736	\$786	\$0
Rhode Island	400% GR	\$4,900,000	\$1,700,000	35%	445	\$397,790	1,096	\$894	\$8,942
South Carolina	300% GR	\$22,178,800	\$2,352,071	11%	2,490	\$2,124,748	7,738	\$853	\$171,111
South Dakota	300% GR	\$593,569	\$0	0%	84	\$84,310	223	\$1,004	--
Tennessee	300% GR	\$24,800,253	\$7,200,000	29%	2,372	\$1,526,669	3,943	\$644	\$650,505
Texas	200% GR	\$94,247,608	\$26,887,609	29%	7,686	\$7,351,624	18,244	\$957	\$710,777
Utah	250% GR	\$4,959,192	\$94,412	2%	430	\$355,702	1,403	\$827	\$99,435
Vermont	200% NET	\$1,053,006	\$140,000	13%	132	\$65,803	308	\$499	\$65,803
Virgin Islands (U.S.)	400% GR	\$399,738	\$0	0%	123	--	--	--	--
Virginia <sup>5</sup>	400% GR	\$22,042,170	\$850,000	4%	1,748	\$3,390,451	5,304	\$1,940	--
Washington	300% GR	\$27,169,351	\$8,944,861	33%	2,476	\$996,543	6,501	\$402	\$500,476
West Virginia	325% GR	\$2,829,300	\$0	0%	237	\$259,027	685	\$1,093	\$10,537
Wisconsin	300% GR	\$10,912,911	\$926,200	8%	584	\$710,988	1,625	\$1,217	\$604,007
Wyoming	332% GR	\$1,668,421	\$735,000	44%	75	\$100,021	254	\$1,334	--
<b>Total</b>		<b>\$1,589,761,339</b>	<b>\$215,958,612</b>	<b>14%</b>	<b>125,479</b>	<b>\$125,838,306</b>	<b>416,590</b>	<b>\$1,003</b>	<b>\$10,847,500</b>

<sup>1</sup> The 2009 Federal Poverty Level (FPL) was \$10,830 (slightly higher in Alaska and Hawaii) for a household of one. GR=Gross income; NET=Net income.

<sup>2</sup> The total FY2009 budget includes federal, state, and drug rebate dollars. Cost recovery funds, with the exception of drug rebate dollars, are not included in the total budget.

<sup>3</sup> Per capita expenditures calculation based on June 2009 clients served and drug expenditures.

Note: The number of ADAPs reporting data for each category varies. See Summary Table II and Tables VII, XI, XII, and XV for additional detail. A dash (--) indicates no data available from the ADAP.

A zero (\$0 or 0) indicates a response of zero (\$0 or 0) from the ADAP.

Summary Table II

Total Clients Enrolled/Served, Drug Expenditures, and Prescriptions Filled, June 2008 and June 2009

State/Territory	June 2008 Clients Enrolled	June 2009 Clients Enrolled	% Change	June 2008 Clients Served	June 2009 Clients Served	% Change	June 2008 Drug Expenditures	June 2009 Drug Expenditures	% Change	June 2008 Prescriptions Filled	June 2009 Prescriptions Filled	% Change
Alabama	1,439	1,420	-1%	1,207	1,335	11%	\$1,132,283	\$1,484,333	31%	3,219	4,637	44%
Alaska	63	78	24%	57	63	11%	\$51,583	\$88,957	72%	163	232	42%
American Samoa	--	--	--	--	--	--	--	--	--	--	--	--
Arizona	2,025	1,113	-45%	949	1,032	9%	\$1,067,035	\$1,179,812	11%	5,297	4,234	-20%
Arkansas	511	664	30%	393	469	19%	\$328,028	\$417,336	27%	1,294	1,786	38%
California	30,320	33,074	9%	20,471	23,027	12%	\$26,723,020	\$32,060,460	20%	80,522	92,769	15%
Colorado	1,440	2,673	86%	934	2,257	142%	\$852,900	\$1,006,183	18%	2,775	3,472	25%
Connecticut	1,771	1,928	9%	1,271	1,439	13%	\$1,360,911	\$1,806,598	33%	4,946	5,073	3%
Delaware	660	970	47%	380	531	40%	\$158,623	\$185,144	17%	1,493	2,011	35%
District of Columbia	1,619	2,227	38%	927	1,454	57%	\$772,698	\$1,441,644	87%	3,010	3,859	28%
Federated States of Micronesia	--	--	--	--	--	--	--	--	--	--	--	--
Florida	10,757	13,283	23%	10,738	13,258	23%	\$3,860,505	\$5,747,226	49%	17,792	27,992	57%
Georgia	4,190	4,615	10%	3,600	3,878	8%	\$3,384,880	\$3,849,672	14%	10,728	11,917	11%
Guam	5	4	-20%	5	4	-20%	\$17,562	\$8,090	-54%	42	18	-57%
Hawaii	272	279	3%	247	227	-8%	\$266,085	\$209,464	-21%	832	679	-18%
Idaho	149	171	15%	113	121	7%	\$219,238	\$216,444	-1%	326	290	-11%
Illinois	4,528	5,435	20%	3,407	3,865	13%	\$3,341,937	\$3,628,700	9%	9,122	10,056	10%
Indiana	1,318	1,462	11%	1,318	1,462	11%	\$242,591	\$244,966	1%	6,307	7,387	17%
Iowa	366	400	9%	261	356	36%	\$178,617	\$268,944	51%	647	936	45%
Kansas	947	1,088	15%	431	486	13%	\$704,976	\$634,242	-10%	1,070	1,253	17%
Kentucky	1,207	1,351	12%	990	1,286	30%	\$650,562	\$773,654	19%	3,186	3,571	12%
Louisiana	1,572	1,934	23%	1,572	1,934	23%	\$1,374,192	\$2,038,551	48%	3,739	2,488	-33%
Maine	543	600	10%	187	188	1%	\$66,950	\$51,210	-24%	517	600	16%
Marshall Islands	--	--	--	--	--	--	--	--	--	--	--	--
Maryland	4,341	4,801	11%	2,748	3,081	12%	\$2,450,249	\$2,444,882	-0%	9,177	10,156	11%
Massachusetts	4,626	5,028	9%	3,102	3,877	25%	\$464,425	\$362,229	-22%	11,691	10,790	-8%
Michigan	1,939	2,227	15%	1,690	1,860	10%	\$1,624,482	\$1,904,570	17%	6,609	7,526	14%
Minnesota	1,158	1,649	42%	914	594	-35%	\$257,545	\$318,218	24%	1,529	1,243	-19%
Mississippi	1,039	--	--	675	--	--	\$778,240	--	--	2,244	--	--
Missouri	1,854	2,241	21%	1,206	1,376	14%	\$1,613,798	\$1,900,096	18%	4,829	5,280	9%
Montana <sup>1</sup>	93	85	-9%	77	61	-21%	\$52,979	\$62,583	18%	221	169	-24%
Nebraska	384	493	28%	258	268	4%	\$220,746	\$182,601	-17%	809	630	-22%
Nevada	844	916	9%	655	746	14%	\$493,127	\$674,367	37%	1,430	1,885	32%
New Hampshire	350	350	0%	189	209	11%	\$174,429	\$183,018	5%	850	936	10%
New Jersey	5,841	6,291	8%	4,746	4,826	2%	\$6,545,695	\$7,322,639	12%	21,203	22,576	6%
New Mexico <sup>2</sup>	585	618	6%	568	616	8%	\$33,321	\$31,485	--	108	98	-9%
New York	18,034	18,295	1%	13,806	14,399	4%	\$21,414,488	\$22,923,977	7%	56,169	68,412	22%
North Carolina	4,501	5,125	14%	3,286	3,810	16%	\$3,330,568	\$3,618,023	9%	11,233	14,325	28%
North Dakota	64	84	31%	33	40	21%	\$37,857	\$42,900	13%	84	104	24%
Northern Mariana Islands	--	--	--	--	--	--	--	--	--	--	--	--
Ohio	3,593	4,181	16%	1,806	2,109	17%	\$154,334	\$433,274	181%	6,993	6,512	-7%
Oklahoma	1,018	1,161	14%	768	884	15%	\$589,331	\$688,236	17%	1,976	2,857	45%
Oregon	1,857	2,194	18%	1,663	1,861	12%	\$349,769	\$217,047	-38%	5,754	6,273	9%
Pennsylvania	4,986	4,375	-12%	3,383	3,472	3%	\$4,130,405	\$4,807,876	16%	13,896	14,498	4%
Puerto Rico	3,606	4,146	15%	3,210	3,836	20%	\$2,735,978	\$3,014,978	10%	7,094	9,736	37%
Rhode Island	--	771	--	397	445	12%	--	\$397,790	--	--	1,096	--
South Carolina	3,042	3,693	21%	2,172	2,490	15%	\$3,513,143	\$2,124,748	-40%	6,009	7,738	29%
South Dakota	196	85	-57%	77	84	9%	\$64,078	\$84,310	32%	247	223	-10%
Tennessee	2,840	3,527	24%	2,016	2,372	18%	\$1,198,581	\$1,526,669	27%	3,140	3,943	26%
Texas	10,443	12,358	18%	6,750	7,686	14%	\$6,067,800	\$7,351,624	21%	15,650	18,244	17%
Utah	475	505	6%	475	430	-9%	\$438,048	\$355,702	-19%	1,245	1,403	13%
Vermont	259	258	-0%	83	132	59%	--	\$65,803	--	--	308	--
Virgin Islands (U.S.)	--	124	--	85	123	45%	--	--	--	--	0	--
Virginia	2,740	3,003	10%	1,520	1,748	15%	\$1,880,534	\$3,390,451	80%	4,450	5,304	19%
Washington	3,206	3,572	11%	1,310	2,476	89%	\$998,020	\$996,543	-0%	6,714	6,501	-3%
West Virginia	325	348	7%	184	237	29%	\$164,590	\$259,027	57%	468	685	46%
Wisconsin	1,172	1,300	11%	677	584	-14%	\$858,409	\$710,988	-17%	2,307	1,625	-30%
Wyoming	87	134	54%	60	75	25%	\$72,954	\$100,021	37%	210	254	21%
<b>Total</b>	<b>151,200</b>	<b>168,707</b>		<b>110,047</b>	<b>125,479</b>		<b>\$109,463,099</b>	<b>\$125,838,306</b>		<b>361,366</b>	<b>416,590</b>	
<b>Comparison Total<sup>1</sup></b>	<b>150,161</b>	<b>168,060</b>	<b>12%</b>	<b>109,372</b>	<b>125,157</b>	<b>14%</b>	<b>\$108,684,859</b>	<b>\$125,374,714</b>	<b>15%</b>	<b>\$359,122</b>	<b>\$415,186</b>	<b>16%</b>

<sup>1</sup> Comparison Totals are based on only those ADAPs that reported data in both time periods.

Summary Table III

Total Clients Enrolled/Served and Program Expenditures, FY2008<sup>1</sup>

State/Territory	FY2008 Clients Enrolled <sup>2</sup>	FY2008 New Clients Enrolled	FY2008 Clients Served <sup>2</sup>	FY2008 ADAP Expenditures								Total Expenditures
				Prescription Drugs	Insurance Premiums	Insurance Co-payments and Deductibles	Client Outreach	Adherence and Monitoring	Quality Management	Program Administration	Other <sup>3</sup>	
Alabama	1,668	556	1,668	\$14,695,675	\$49,656	\$18,021	\$0	\$325,702	\$0	\$0	\$0	\$15,089,054
Alaska	89	23	87	\$679,360	\$85,000	\$0	\$0	\$0	\$0	\$39,724	\$0	\$804,084
American Samoa	--	--	--	--	--	--	--	--	--	--	--	--
Arizona	1,113	523	1,636	\$11,298,665	\$0	\$0	\$0	\$0	\$12,750	\$276,651	\$0	\$11,588,066
Arkansas	664	349	664	\$4,803,273	\$0	\$307,377	\$0	\$0	\$0	\$0	\$106,972	\$5,217,622
California	39,305	5,190	34,928	\$300,540,209	\$0	\$40,737,526	\$0	\$0	\$0	\$0	\$0	\$341,277,735
Colorado	3,691	1,566	2,137	\$9,522,597	\$968,441	\$1,500,816	\$0	\$408,002	\$286,724	\$813,331	\$0	\$13,499,911
Connecticut	1,852	353	1,391	\$17,370,000	\$0	\$0	\$0	\$254,500	\$395,687	\$467,678	\$0	\$18,487,865
Delaware	1,068	150	898	\$1,306,391	\$111,426	\$0	\$45,000	\$390,375	\$13,429	\$105,266	\$0	\$1,971,887
District of Columbia	1,966	--	2,421	\$9,949,357	\$73,734	\$331,985	\$0	\$605,280	\$558,057	\$0	\$0	\$11,518,413
Federated States of Micronesia	--	--	--	--	--	--	--	--	--	--	--	--
Florida	16,102	3,836	15,024	\$93,763,940	\$2,075,000	\$425,000	\$0	\$0	\$0	\$3,890,182	\$0	\$100,154,122
Georgia	4,212	920	5,833	\$27,875,756	\$1,691,394	\$0	\$0	\$0	\$0	\$0	\$0	\$29,567,150
Guam	4	0	4	\$107,775	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$107,775
Hawaii	361	90	348	\$2,272,977	\$117,780	\$11,029	\$0	\$2,365	\$0	\$45,763	\$104,220	\$2,554,134
Idaho	213	64	195	\$2,614,771	\$0	\$0	\$0	\$10,040	\$0	\$0	\$0	\$2,624,811
Illinois	6,535	1,325	5,237	\$36,577,017	\$0	\$681,376	\$0	\$0	\$0	\$355,748	\$0	\$37,614,141
Indiana	1,549	382	1,549	\$396,480	\$8,027,684	\$3,326,816	\$0	\$0	\$207,295	\$1,036,054	\$0	\$12,994,329
Iowa	503	93	467	\$2,218,012	\$304,847	\$0	\$0	\$0	\$0	\$115,717	\$0	\$2,638,576
Kansas	1,174	433	556	\$2,037,371	\$120,107	\$0	\$0	\$0	\$41,850	\$64,019	\$1,875	\$2,265,222
Kentucky	1,484	346	1,412	\$7,800,774	\$0	\$1,071,982	\$0	\$0	\$0	\$0	\$0	\$8,872,756
Louisiana	3,486	105	3,483	\$17,643,498	\$0	\$326,638	\$0	\$0	\$0	\$0	\$50,151	\$18,020,287
Maine	682	147	376	\$340,695	\$75,471	\$165,643	\$0	\$102,471	\$79,864	\$190,458	\$0	\$954,601
Marshall Islands	--	--	--	--	--	--	--	--	--	--	--	--
Maryland	6,308	1,186	5,439	\$30,508,871	\$7,437,113	\$0	\$0	\$1,396,947	\$0	\$0	\$0	\$39,342,931
Massachusetts	6,278	940	5,181	\$4,341,038	\$9,134,499	\$2,314,363	\$0	\$1,278,192	\$0	\$2,136,051	\$0	\$19,204,143
Michigan	3,115	1,142	2,812	\$10,062,125	\$884,298	\$77,141	\$0	\$73,636	\$117,600	\$466,734	\$0	\$11,681,534
Minnesota	1,609	260	1,210	\$2,421,877	\$2,689,220	\$0	\$0	\$4,077	\$25,944	\$2,162	\$0	\$5,143,281
Mississippi	--	--	--	--	--	--	--	--	--	--	--	--
Missouri	2,868	523	2,205	\$17,116,146	\$0	\$1,183,526	\$0	\$0	\$42,697	\$77,120	\$0	\$18,419,489
Montana	118	13	115	\$690,368	\$0	\$55,758	\$0	\$0	\$0	\$0	\$0	\$746,125
Nebraska	483	76	470	\$2,724,293	\$3,090	\$148,056	\$0	\$16,293	\$0	\$153,966	\$0	\$3,045,698
Nevada	--	288	--	\$4,500,090	\$376,727	\$0	\$18,067	\$339,578	\$104,805	\$756,705	\$1,932,327	\$8,028,299
New Hampshire	373	31	373	\$1,752,987	\$246,797	\$285,313	\$0	\$0	\$0	\$203,522	\$62,000	\$2,550,619
New Jersey	8,162	1,318	7,246	\$81,727,371	\$3,002,193	\$0	\$903,980	\$771,324	\$0	\$341,039	\$0	\$86,745,907
New Mexico	812	308	800	\$454,652	\$2,076,519	\$0	\$0	\$0	\$2,444	\$219,925	\$0	\$2,753,540
New York	22,737	3,353	20,349	\$260,769,839	\$16,621,895	\$0	\$530,608	\$3,282,188	\$693,873	\$285,712	\$2,571,410	\$284,755,525
North Carolina	6,064	3,629	5,279	\$38,046,726	\$0	\$158,789	\$0	\$0	\$0	\$1,761,156	\$0	\$39,966,671
North Dakota	68	8	65	\$467,422	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$467,422
Northern Mariana Islands	--	--	--	--	--	--	--	--	--	--	--	--
Ohio	4,940	937	3,896	\$9,439,253	\$1,952,894	\$2,296,978	\$0	\$0	\$0	\$1,952,894	\$0	\$15,642,018
Oklahoma	1,257	236	1,192	\$6,817,907	\$529,351	\$672,621	\$0	\$73,022	\$186,674	\$283,396	\$291,997	\$8,854,968
Oregon	2,351	425	1,392	\$2,332,091	\$1,294,230	\$1,953,093	\$0	\$0	\$0	\$0	\$0	\$5,579,414
Pennsylvania	8,091	1,551	5,203	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Puerto Rico	4,002	458	4,002	\$28,896,399	\$0	\$0	\$0	\$116,651	\$0	\$453,878	\$23,373	\$29,490,301
Rhode Island	728	167	716	\$4,378,910	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$4,378,910
South Carolina	3,722	748	3,573	\$13,158,482	\$351,466	\$958,699	\$0	\$0	\$0	\$1,177,293	\$0	\$15,645,941
South Dakota	170	26	116	\$884,059	\$0	\$0	\$0	\$0	\$3,831	\$3,500	\$0	\$891,390
Tennessee	3,502	1,109	3,605	\$14,595,313	\$5,201,440	\$2,447,736	\$0	\$0	\$0	\$0	\$0	\$22,244,489
Texas	14,160	2,144	12,425	\$76,034,058	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$76,034,058
Utah	614	71	504	\$2,151,116	\$519,238	\$0	\$0	\$0	\$18,110	\$290,572	\$0	\$2,979,036
Vermont	275	46	105	\$631,001	\$114,643	\$0	\$0	\$0	\$10,872	\$58,485	\$0	\$815,001
Virgin Islands (U.S.)	145	33	103	\$583,401	\$3,279	\$0	\$0	\$0	\$28,135	\$128,837	\$378,358	\$1,122,010
Virginia	3,873	1,035	3,588	\$19,557,944	\$0	\$0	\$0	\$700,247	\$18,057	\$589,481	\$0	\$20,865,729
Washington	4,091	563	3,509	\$14,415,877	\$10,795,423	\$1,302,256	\$0	\$0	\$175,471	\$866,219	\$0	\$27,555,246
West Virginia	414	70	292	\$2,292,983	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$2,292,983
Wisconsin	1,476	253	1,232	\$5,896,147	\$2,780,739	\$2,940,834	\$0	\$0	\$0	\$208,364	\$0	\$11,826,084
Wyoming	146	39	99	\$1,210,943	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$1,210,943
<b>Total</b>	<b>200,673</b>	<b>39,437</b>	<b>177,410</b>	<b>\$1,222,674,280</b>	<b>\$79,715,593</b>	<b>\$65,699,372</b>	<b>\$1,497,655</b>	<b>\$10,150,890</b>	<b>\$3,024,169</b>	<b>\$19,817,602</b>	<b>\$5,522,683</b>	<b>\$1,408,102,244</b>

<sup>1</sup> This table represents ADAP program expenditures in FY2008 (April 1, 2008-March 31, 2009). Only expenditure categories requested in the National ADAP Monitoring Survey are represented in this table.


<sup>2</sup> For some states, enrolled clients reported may be a snapshot in time rather than a cumulative unduplicated client count. In this instance, some ADAPs may report a higher number of clients served throughout the fiscal year compared to the number of clients enrolled in the program at the end of the fiscal year.

<sup>3</sup> "Other" includes, but is not limited to, contract services to dispense medications, determine eligibility, and manage enrollment; pharmacy charges, dispensing and shipping fees, central pharmacy fees; as well as medical, dental, lab, and nutritional services.




## Charts

Chart 1  
ADAP Client Enrollment, June 2003-2009



Note: Includes clients enrolled by ADAPs reporting data for June in a given year. Data on client enrollment in ADAP is not available prior to June 2003.


Chart 2  
ADAP Clients Enrolled and Top Ten States, by Clients Enrolled, FY2008



State	Clients Enrolled, FY2008
California	39,305
New York	22,737
Florida	16,102
Texas	14,160
New Jersey	8,162
Pennsylvania	8,091
Illinois	6,535
Maryland	6,306
Massachusetts	6,278
North Carolina	6,064
<b>Total</b>	<b>133,740</b>


Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands, Rhode Island did not report data. See Summary Table III.

Chart 3  
ADAP Client Utilization, June 1996-2009



Note: Includes clients served by ADAPs reporting data for June in a given year.


Chart 4  
ADAP Clients Served and Top Ten States, by Clients Served, June 2009



State	Clients Served, June 2009
California	23,027
New York	14,399
Florida	13,258
Texas	7,686
New Jersey	4,826
Georgia	3,878
Massachusetts	3,877
Illinois	3,865
Puerto Rico	3,836
North Carolina	3,810
<b>Total</b>	<b>82,462</b>


Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. See Summary Table II.

Chart 5  
Trends in ADAP Client Utilization, June 1996-2009




Note: Includes clients served by ADAPs reporting data for June in a given year.

Chart 6  
ADAP Clients Served, by Race/Ethnicity, June 2009




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. Percentages may not total 100% due to rounding. See Table I.

Chart 7  
ADAP Clients Served, by Gender, June 2009




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. Percentages may not total 100% due to rounding. See Table II.

Chart 8  
ADAP Clients Served, by Age, June 2009




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. Percentages may not total 100% due to rounding. See Table III.

Chart 9  
ADAP Clients Served, by Income Level, June 2009




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. The 2009 Federal Poverty Level (FPL) was \$10,830 (slightly higher in Alaska and Hawaii) for a household of one. Percentages may not total 100% due to rounding. See Table IV.

Chart 10  
ADAP Clients Served, by Insurance Status, June 2009




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. Insurance categories are not mutually exclusive. The overall percentage of clients insured in each category is calculated separately based on reported data. See Table V.

Chart 11  
ADAP Clients by CD4 Count, Enrolled During 12-Month Period, June 2009



Note: 36 ADAPs reported data. See Table VI.

Chart 12  
The National ADAP Budget, FY1996-2009



Note: The total FY2009 budget includes federal, state, and drug rebate dollars. Cost recovery funds, with the exception of drug rebate dollars, are not included in the total budget. Percentages represent changes between the year indicated and the previous year, not aggregate changes since FY1996.

Chart 13  
National ADAP Budget, by Source, FY1996-FY2009






Chart 14  
The National ADAP Budget, by Source, FY2009




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report FY2009 data, but their federal ADAP earmark awards were known and incorporated. The total FY2009 budget does not include cost recovery funds, with the exception of drug rebate dollars. See Table VII.

Chart 15  
Number of ADAPs, by Budget Source, FY2009




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report FY2009 data, but their federal ADAP earmark awards were known and incorporated. See Table VII.

Chart 16  
Number of ADAPs with Funding Decreases, by Budget Source, FY2008-2009




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report FY2009 data, but their federal ADAP earmark awards were known and incorporated. See Tables VIII and IX.

Chart 17  
Part B ADAP Earmark, FY1996-2009




Note: ADAP earmark does not include ADAP Supplemental Fund set-aside from FY2001-2009. Percentages represent changes between the year indicated and the previous year, not aggregate changes since FY1996.

Chart 18  
Part B ADAP Supplemental Funding, FY2001-2009




Note: All Part B ADAP supplemental funds are reported. Percentages represent changes between the year indicated and the previous year, not aggregate changes since FY2001.

Chart 19  
Part B Base Contribution Directed to ADAP, FY1996-2009




Note: Percentages represent changes between the year indicated and the previous year, not aggregate changes since FY1996.

Chart 20  
Part A Contribution Directed to ADAP, FY1996-2009




Note: Percentages represent changes between the year indicated and the previous year, not aggregate changes since FY1996.

Chart 21  
State Funding, FY1996-2009



Note: Percentages represent changes between the year indicated and the previous year, not aggregate changes since FY1996.

Chart 22  
Drug Rebates, FY1996-2009



Note: Percentages represent changes between the year indicated and the previous year, not aggregate changes since FY1996.

Chart 23  
 Cost Recovery and Other Cost-Saving Mechanisms (Excluding Drug Rebates), FY2009




Chart 24  
 Percent Change in ADAP Drug Expenditures, June 1996-2009





Chart 25  
ADAP Drug Expenditures and Top 10 States, by Drug Expenditures, June 2009



	Drug Expenditures, June 2009
California	\$32,060,460
New York	\$22,923,977
Texas	\$7,351,624
New Jersey	\$7,322,639
Florida	\$5,747,226
Pennsylvania	\$4,807,876
Georgia	\$3,849,672
Illinois	\$3,628,700
Virginia	\$3,390,451
North Carolina	\$3,618,023
<b>Total</b>	<b>\$94,700,648</b>

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. See Table XI.

Chart 26  
ADAP Per Capita Drug Expenditures, June 1996-2009






Chart 27a  
 ADAP Drug Expenditures (Including Drug Purchases and Co-Payments), June 2009




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. See Table XI.

Chart 27b  
 ADAP Prescriptions Filled (Including Drug Purchases and Co-Payments), June 2009




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. See Table XII.

Chart 28  
ADAPs Paying Co-Payments on Behalf of Clients, June 2009




Note: 51 ADAPs reported data. American Samoa, Federated States Micronesia, Marshall Islands, Mississippi, Northern Mariana Islands, and U.S. Virgin Islands did not report data.

Chart 29  
ADAP Drug Expenditures, by Drug Class, June 2009




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. Percentages may not total 100% due to rounding. "A1" OIs=Drugs recommended ("A1") for the prevention and treatment of opportunistic infections (OIs). See Table XIII.

Chart 30  
ADAP Prescriptions Filled, by Drug Class, June 2009



Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. Percentages may not total 100% due to rounding. "A1" OIs=Drugs recommended ("A1") for the prevention and treatment of opportunistic infections (OIs). See Table XIV.

Chart 31  
ADAP Drug Purchasing Mechanisms, FY 2009



Note: 54 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, and Northern Mariana Islands did not report data. See Glossary for definitions of purchasing mechanisms.

Chart 32a  
 Clients Served in Insurance Purchasing/Maintenance Programs, June 2002-2009






Chart 32b  
 Estimated ADAP Spending on Insurance Purchasing/Maintenance Programs, FY2002-2009




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. Health insurance programs include purchasing health insurance and paying insurance premiums, co-payments, and/or deductibles. Client data for June 2002 and 2003 represent clients enrolled; June 2004-2009 data represent clients served. All ADAPs that have reported having insurance purchasing/maintenance programs since 2002 are included. See Table XV.

Chart 33  
ADAP Income Eligibility, June 30, 2009




Note: 53 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. The 2009 Federal Poverty Level (FPL) was \$10,830 (slightly higher in Alaska and Hawaii) for a household of one.

Chart 34  
ADAP Enrollment Processes, June 2009




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. Enrollment categories are not mutually exclusive. ASOs=AIDS Services Organizations; CBOs=Community-Based Organizations. See Table XVII.

Chart 35  
ADAP Policies Related to Medicare Part D, June 2009




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. See Table XIX.

Chart 36  
Number of States with ADAP Waiting Lists, by Survey Period, July 2002-March 2010




Note: PAI = President's ADAP Initiative. See Table XXII.

Chart 37  
 Number of People on ADAP Waiting Lists, by Survey Period, July 2002-March 2010



Note: PAI = President's ADAP Initiative. See Table XXII.


Chart 38  
 ADAP Formulary Coverage of Antiretroviral Drugs, December 31, 2009



Note: 54 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, and Northern Mariana Islands did not report data.

Chart 39

ADAP Formulary Coverage of Drugs Recommended (“A1”) for Prevention and Treatment of Opportunistic Infections (OIs), December 31, 2009



Note: 54 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, and Northern Mariana Islands did not report data.

## Tables

Table I  
ADAP Clients Served, by Race/Ethnicity, June 2009

State/Territory	June 2009 Clients Served	Non-Hispanic Black/African American	Non-Hispanic White	Hispanic	Asian	Native Hawaiian/Pacific Islander	American Indian/Alaskan Native	Multi-Racial	Other	Unknown
Alabama	1,335	61%	34%	4%	1%	0%	0.07%	0%	0%	0%
Alaska	63	8%	56%	27%	5%	0%	3%	0%	0%	2%
American Samoa	--	--	--	--	--	--	--	--	--	--
Arizona	1,032	7%	44%	45%	1%	0%	2%	0.3%	0%	0%
Arkansas	469	40%	52%	6%	0%	0%	0.4%	0.6%	0.9%	0%
California	23,027	12%	39%	39%	3%	0.3%	0.3%	5%	0%	1%
Colorado	2,257	14%	56%	26%	1%	0.8%	2%	0.5%	0%	0.8%
Connecticut	1,439	36%	41%	22%	0.8%	0.1%	0.5%	0%	0%	0%
Delaware	531	63%	30%	5%	0.2%	0%	0%	2%	0%	0%
District of Columbia	1,454	77%	9%	9%	0.4%	0%	0.2%	0.6%	0%	3%
Federated States of Micronesia	--	--	--	--	--	--	--	--	--	--
Florida	13,258	41%	30%	28%	0.4%	0.2%	0.1%	0.2%	0.1%	0%
Georgia	3,878	58%	24%	5%	0.6%	0.03%	0.1%	2%	11%	0.3%
Guam	4	0%	20%	0%	0%	80%	0%	0%	0%	0%
Hawaii	227	4%	55%	14%	11%	9%	0.4%	7%	0%	0%
Idaho	121	3%	74%	20%	0%	0%	0.8%	2%	0%	0%
Illinois	3,865	22%	27%	25%	1%	0.03%	0%	3%	4%	18%
Indiana	1,462	19%	70%	7%	0.5%	0%	0.1%	0.5%	3%	0.1%
Iowa	356	19%	63%	13%	2%	0%	0.3%	2%	0%	0.6%
Kansas	486	22%	48%	14%	0.8%	0%	0.6%	11%	0%	4%
Kentucky	1,286	27%	66%	6%	0.4%	0.2%	0.2%	0.3%	0.2%	0%
Louisiana	1,934	44%	24%	3%	0.1%	0.1%	0.1%	2%	0%	26%
Maine	188	7%	82%	4%	0.5%	0%	3%	2%	2%	0%
Marshall Islands	--	--	--	--	--	--	--	--	--	--
Maryland	3,081	67%	18%	6%	0.5%	0.1%	0.2%	7%	0.1%	0.8%
Massachusetts	3,877	23%	45%	22%	2%	0.1%	0.2%	1%	8%	0%
Michigan	1,860	39%	48%	7%	0.8%	0.1%	0.4%	3%	0.5%	0.7%
Minnesota	594	25%	47%	16%	2%	0.2%	1%	0.5%	0.2%	8%
Mississippi	--	--	--	--	--	--	--	--	--	--
Missouri	1,376	45%	49%	4%	0.3%	0.07%	0.1%	0.4%	0%	0.9%
Montana	61	3%	72%	7%	0%	0%	16%	2%	0%	0%
Nebraska	268	25%	51%	22%	0.7%	0.7%	0.7%	0%	0%	0%
Nevada	746	18%	46%	30%	1%	1%	1%	0.3%	2%	0.4%
New Hampshire	209	14%	70%	12%	0.5%	0%	1%	2%	0%	0.5%
New Jersey	4,826	47%	21%	26%	1%	0.2%	0%	0%	0%	4%
New Mexico	616	4%	42%	48%	0.8%	0%	4%	0%	0.5%	0%
New York	14,399	34%	29%	30%	2%	0.2%	0.4%	0%	0%	5%
North Carolina	3,810	56%	32%	9%	0.7%	0%	0.6%	0%	2%	0%
North Dakota	40	15%	78%	0%	0%	0%	8%	0%	0%	0%
Northern Mariana Islands	--	--	--	--	--	--	--	--	--	--
Ohio	2,109	35%	56%	3%	1%	0.1%	0.5%	1%	2%	1%
Oklahoma	884	15%	69%	8%	0.6%	0.3%	7%	0%	0.1%	0%
Oregon	1,861	7%	72%	16%	1%	0.3%	1%	2%	0.4%	0.2%
Pennsylvania	3,472	42%	41%	9%	0.8%	0%	0.4%	0%	1%	6%
Puerto Rico	3,836	0%	0%	100%	0%	0%	0%	0%	0%	0%
Rhode Island	445	25%	50%	19%	1%	0%	1%	2%	2%	0.2%
South Carolina	2,490	66%	28%	5%	0.3%	0.04%	0.2%	1%	0.1%	0%
South Dakota	84	30%	58%	0%	0%	0%	12%	0%	0%	0%
Tennessee	2,372	49%	42%	4%	0.7%	0.1%	0.1%	0.1%	4%	0.3%
Texas	7,686	30%	25%	42%	0.9%	0%	0.2%	0%	0.8%	0.8%
Utah	430	5%	66%	25%	0.2%	0%	2%	0%	0.7%	0.2%
Vermont	132	8%	82%	7%	0.8%	0%	2%	0.8%	0%	0%
Virgin Islands (U.S.)	123	69%	14%	16%	0%	0%	0%	0.8%	0%	0%
Virginia	1,748	53%	28%	9%	1%	0.1%	0.3%	0%	0.5%	8%
Washington	2,476	13%	57%	17%	2%	0.4%	1%	6%	1%	3%
West Virginia	237	14%	84%	1%	1%	0%	0%	0%	0%	0%
Wisconsin	584	32%	45%	20%	1%	0%	0.9%	0%	0.7%	0.7%
Wyoming	75	5%	81%	0%	1%	1%	11%	0%	0%	0%
<b>Total</b>	<b>125,479</b>	<b>32%</b>	<b>35%</b>	<b>26%</b>	<b>1%</b>	<b>0.2%</b>	<b>0.4%</b>	<b>2%</b>	<b>1%</b>	<b>2%</b>

Table II  
ADAP Clients Served, by Gender, June 2009

State/Territory	June 2009 Clients Served	Male	Female	Transgender	Unknown
Alabama	1,335	72%	28%	0%	0%
Alaska	63	79%	21%	0%	0%
American Samoa	--	--	--	--	--
Arizona	1,032	82%	18%	0%	0%
Arkansas	469	80%	20%	0%	0%
California	23,027	91%	9%	0.5%	0%
Colorado	2,257	87%	13%	0.4%	0.04%
Connecticut	1,439	72%	28%	0%	0%
Delaware	531	46%	34%	0.4%	0%
District of Columbia	1,454	76%	23%	0.6%	0.003%
Federated States of Micronesia	--	--	--	--	--
Florida	13,258	73%	27%	0.3%	0%
Georgia	3,878	73%	27%	0.2%	0.03%
Guam	4	60%	40%	0%	0%
Hawaii	227	89%	11%	0.4%	0%
Idaho	121	79%	21%	0%	0%
Illinois	3,865	82%	17%	0%	1%
Indiana	1,462	82%	18%	0%	0%
Iowa	356	78%	22%	0.8%	0%
Kansas	486	78%	22%	0%	0.2%
Kentucky	1,286	83%	17%	0.2%	0%
Louisiana	1,934	72%	27%	0.1%	0%
Maine	188	85%	15%	0%	0%
Marshall Islands	--	--	--	--	--
Maryland	3,081	64%	36%	0%	0%
Massachusetts	3,877	96%	30%	0.1%	0%
Michigan	1,860	83%	16%	0.1%	0%
Minnesota	594	74%	26%	0%	0%
Mississippi	--	--	--	--	--
Missouri	1,376	81%	19%	0.1%	0%
Montana	61	75%	25%	0%	0%
Nebraska	268	76%	24%	0%	0%
Nevada	746	80%	20%	0.1%	0%
New Hampshire	209	78%	22%	0.5%	0%
New Jersey	4,826	65%	33%	0%	0%
New Mexico	616	91%	9%	0%	0%
New York	14,399	75%	24%	0.1%	0.04%
North Carolina	3,810	71%	29%	0.1%	0%
North Dakota	40	70%	30%	0%	0%
Northern Mariana Islands	--	--	--	--	--
Ohio	2,109	81%	18%	0.1%	0.2%
Oklahoma	884	85%	15%	0.1%	0%
Oregon	1,861	87%	12%	0.5%	0%
Pennsylvania	3,472	76%	24%	0%	0%
Puerto Rico	3,836	39%	61%	0%	0%
Rhode Island	445	21%	79%	0.2%	0%
South Carolina	2,490	70%	30%	0.2%	0%
South Dakota	84	71%	29%	0%	0%
Tennessee	2,372	77%	23%	0.2%	0%
Texas	7,686	76%	24%	0.3%	0%
Utah	430	87%	13%	0%	0.2%
Vermont	132	86%	14%	0%	0%
Virgin Islands (U.S.)	123	64%	36%	0%	0%
Virginia	1,748	69%	28%	0.2%	2%
Washington	2,476	87%	12%	0.5%	0%
West Virginia	237	80%	20%	0%	0%
Wisconsin	584	85%	14%	0.9%	0%
Wyoming	75	76%	24%	0%	0%
<b>Total</b>	<b>125,479</b>	<b>78%</b>	<b>23%</b>	<b>0.2%</b>	<b>0.1%</b>

Table III  
ADAP Clients Served, by Age, June 2009

State/Territory	June 2009 Clients Served	≤12 Years	13-24 Years	25-44 Years	45-64 Years	>64 Years	Age Unknown
Alabama	1,335	0%	13%	56%	31%	0%	0%
Alaska	63	0%	2%	43%	51%	5%	0%
American Samoa	--	--	--	--	--	--	--
Arizona	1,032	0.1%	3%	48%	47%	2%	0%
Arkansas	469	0%	4%	47%	47%	2%	0%
California	23,027	0%	2%	47%	48%	4%	0%
Colorado	2,257	0.04%	2%	50%	45%	3%	0%
Connecticut	1,439	0%	2%	36%	57%	5%	0%
Delaware	531	0.2%	1%	39%	56%	3%	0%
District of Columbia	1,454	0%	3%	48%	47%	2%	0%
Federated States of Micronesia	--	--	--	--	--	--	--
Florida	13,258	0.1%	2%	45%	50%	2%	0%
Georgia	3,878	0.1%	9%	62%	28%	0.7%	0%
Guam	4	0%	0%	60%	40%	0%	0%
Hawaii	227	0%	1%	30%	62%	7%	0%
Idaho	121	0%	2%	55%	42%	1%	0%
Illinois	3,865	0.03%	6%	55%	37%	1%	0%
Indiana	1,462	0.1%	2%	46%	49%	2%	0%
Iowa	356	0.3%	3%	55%	39%	3%	0%
Kansas	486	0%	3%	49%	47%	2%	0%
Kentucky	1,286	0.1%	2%	48%	47%	3%	0%
Louisiana	1,934	0.1%	4%	50%	44%	2%	0%
Maine	188	0%	2%	35%	60%	4%	0%
Marshall Islands	--	--	--	--	--	--	--
Maryland	3,081	0.2%	2%	43%	52%	3%	0%
Massachusetts	3,877	0.2%	1%	39%	57%	4%	0%
Michigan	1,860	0%	2%	47%	48%	3%	0%
Minnesota	594	0.7%	3%	52%	43%	2%	0%
Mississippi	--	--	--	--	--	--	--
Missouri	1,376	0.2%	5%	56%	38%	0.7%	0%
Montana	61	0%	0%	44%	56%	0%	0%
Nebraska	268	1%	1%	53%	43%	1%	0%
Nevada	746	0.1%	4%	54%	40%	2%	0%
New Hampshire	209	0%	2%	36%	58%	4%	0%
New Jersey	4,826	0.2%	3%	41%	52%	2%	0%
New Mexico	616	0%	3%	42%	54%	1%	0%
New York	14,399	0.1%	2%	43%	51%	4%	0%
North Carolina	3,810	0%	4%	51%	42%	2%	1%
North Dakota	40	0%	3%	53%	45%	0%	0%
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	2,109	0.0%	7%	43%	47%	3%	0%
Oklahoma	884	0%	2%	53%	44%	1%	0%
Oregon	1,861	0%	3%	50%	45%	2%	0%
Pennsylvania	3,472	0.1%	2%	40%	54%	4%	0%
Puerto Rico	3,836	0.5%	4%	39%	53%	3%	0%
Rhode Island	445	0%	2%	43%	51%	3%	0%
South Carolina	2,490	0.1%	3%	48%	48%	1%	0%
South Dakota	84	0%	2%	45%	50%	2%	0%
Tennessee	2,372	0.1%	3%	54%	42%	0.6%	0%
Texas	7,686	0.1%	3%	57%	40%	0.7%	0%
Utah	430	0.5%	1%	52%	44%	2%	0%
Vermont	132	0%	1%	40%	56%	3%	0%
Virgin Islands (U.S.)	123	0%	3%	57%	37%	3%	0%
Virginia	1,748	0.1%	6%	54%	38%	1%	0.2%
Washington	2,476	0%	2%	47%	48%	3%	0%
West Virginia	237	0.4%	2%	46%	48%	4%	0%
Wisconsin	584	0%	4%	53%	42%	1%	0%
Wyoming	75	0%	1%	44%	52%	3%	0%
<b>Total</b>	<b>125,479</b>	<b>0.1%</b>	<b>3%</b>	<b>47%</b>	<b>47%</b>	<b>3%</b>	<b>0.04%</b>

Table IV  
ADAP Clients Served, by Income Level, June 2009

State/Territory	June 2009 Clients Served	≤ 100% FPL	101-200% FPL	201-300% FPL	301-400% FPL	>400% FPL	Unknown
Alabama	1,335	40%	52%	8%	0%	0%	0%
Alaska	63	32%	48%	21%	0%	0%	0%
American Samoa	--	--	--	--	--	--	--
Arizona	1,032	7%	19%	74%	0%	0%	0%
Arkansas	469	54%	36%	7%	2%	0.85%	0%
California	23,027	41%	31%	18%	9%	1%	0.2%
Colorado	2,257	0%	0%	0%	0%	0%	100%
Connecticut	1,439	30%	46%	19%	5%	0%	0%
Delaware	531	51%	27%	13%	6%	3%	0%
District of Columbia	1,454	60%	23%	11%	4%	1%	0.2%
Federated States of Micronesia	--	--	--	--	--	--	--
Florida	13,258	50%	34%	13%	3%	0%	0%
Georgia	3,878	49%	39%	11%	0%	0%	0.7%
Guam	4	0%	100%	0%	0%	0%	0%
Hawaii	227	35%	45%	17%	4%	0%	0%
Idaho	121	67%	33%	0%	0%	0%	0%
Illinois	3,865	51%	28%	15%	5%	1%	0%
Indiana	1,462	43%	43%	14%	0%	0%	0%
Iowa	356	46%	35%	7%	0%	0%	11%
Kansas	486	46%	33%	20%	1%	0%	0%
Kentucky	1,286	18%	82%	0%	0%	0%	0%
Louisiana	1,934	18%	11%	2%	0%	0%	69%
Maine	188	44%	31%	19%	4%	2%	0%
Marshall Islands	--	--	--	--	--	--	--
Maryland	3,081	21%	34%	23%	14%	8%	0%
Massachusetts	3,877	41%	27%	15%	11%	6%	0%
Michigan	1,860	21%	41%	16%	7%	1%	13%
Minnesota	594	22%	39%	30%	7%	3%	0%
Mississippi	--	--	--	--	--	--	--
Missouri	1,376	52%	33%	15%	0%	0%	0%
Montana	61	20%	41%	18%	8%	2%	11%
Nebraska	268	0%	100%	0%	0%	0%	0%
Nevada	746	49%	34%	13%	4%	0%	0%
New Hampshire	209	29%	53%	18%	0%	0%	0%
New Jersey	4,826	42%	23%	17%	11%	4%	0%
New Mexico	616	53%	34%	13%	0%	0%	0%
New York	14,399	38%	30%	19%	13%	1%	0%
North Carolina	3,810	53%	37%	10%	0%	0%	0%
North Dakota	40	38%	30%	25%	8%	0%	0%
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	2,109	75%	20%	4%	0%	0%	0%
Oklahoma	884	38%	47%	15%	0%	0%	0%
Oregon	1,861	48%	38%	13%	1%	0%	0%
Pennsylvania	3,472	10%	38%	27%	11%	5%	9%
Puerto Rico	3,836	97%	3%	0%	0%	0%	0%
Rhode Island	445	0%	0%	0%	0%	0%	100%
South Carolina	2,490	46%	31%	16%	6%	1%	0%
South Dakota	84	36%	35%	30%	0%	0%	0%
Tennessee	2,372	72%	21%	6%	0.3%	0%	0%
Texas	7,686	62%	39%	0%	0%	0%	0%
Utah	430	37%	31%	21%	11%	0%	0%
Vermont	132	0%	100%	0%	0%	0%	0%
Virgin Islands (U.S.)	123	49%	30%	14%	7%	0%	1%
Virginia	1,748	64%	26%	8%	1%	0%	1%
Washington	2,476	32%	39%	24%	4%	0%	0%
West Virginia	237	47%	32%	16%	5%	0%	0%
Wisconsin	584	47%	31%	20%	0.2%	0%	1%
Wyoming	75	0%	0%	0%	0%	0%	0%
<b>Total</b>	<b>125,479</b>	<b>45%</b>	<b>32%</b>	<b>14%</b>	<b>6%</b>	<b>1%</b>	<b>2%</b>

Table V  
ADAP Clients Served, by Insurance Status, June 2009

State/Territory	June 2009 Clients Served	Medicaid	Medicare	Dually Eligible <sup>1</sup>	Private Insurance	Uninsured
Alabama	1,335	0%	4%	0%	0%	100%
Alaska	63	0%	6%	0%	29%	51%
American Samoa	--	--	--	--	--	--
Arizona	1,032	0%	46%	0%	0%	62%
Arkansas	469	3%	19%	0%	3%	74%
California	23,027	1%	9%	6%	18%	65%
Colorado	2,257	0%	39%	8%	0%	65%
Connecticut	1,439	0%	24%	0%	67%	43%
Delaware	531	17%	10%	7%	26%	18%
District of Columbia	1,454	0%	10%	0%	14%	0%
Federated States of Micronesia	--	--	--	--	--	--
Florida	13,258	1%	1%	1%	4%	60%
Georgia	3,878	2%	5%	0%	0%	93%
Guam	4	0%	50%	0%	0%	25%
Hawaii	227	0%	30%	0%	31%	38%
Idaho	121	0%	0%	0%	0%	100%
Illinois	3,865	2%	0%	0%	6%	93%
Indiana	1,462	0%	28%	0%	0%	72%
Iowa	356	2%	11%	2%	20%	70%
Kansas	486	20%	16%	31%	37%	73%
Kentucky	1,286	0%	36%	10%	40%	44%
Louisiana	1,934	0%	4%	0%	0%	0%
Maine	188	56%	9%	11%	11%	13%
Marshall Islands	--	--	--	--	--	--
Maryland	3,081	0%	20%	0%	25%	55%
Massachusetts	3,877	39%	2%	27%	15%	8%
Michigan	1,860	0%	15%	0%	35%	0%
Minnesota	594	65%	75%	35%	47%	0%
Mississippi	--	--	--	--	--	--
Missouri	1,376	0%	6%	0%	32%	68%
Montana	61	0%	0%	0%	13%	87%
Nebraska	268	0%	9%	0%	28%	97%
Nevada	746	0%	20%	4%	16%	81%
New Hampshire	209	0%	0%	0%	0%	0%
New Jersey	4,826	0%	5%	0%	29%	99%
New Mexico	616	0%	0%	0%	0%	6%
New York	14,399	3%	18%	0%	27%	67%
North Carolina	3,810	0%	11%	0%	0%	0%
North Dakota	40	23%	20%	5%	38%	50%
Northern Mariana Islands	--	--	--	--	--	--
Ohio	2,109	18%	33%	24%	47%	76%
Oklahoma	884	9%	29%	9%	27%	52%
Oregon	1,861	12%	39%	10%	26%	4%
Pennsylvania	3,472	0%	13%	0%	23%	74%
Puerto Rico	3,836	97%	0%	0%	0%	1%
Rhode Island	445	--	--	--	--	--
South Carolina	2,490	0%	4%	0%	17%	83%
South Dakota	84	11%	15%	0%	37%	37%
Tennessee	2,372	0%	0%	0%	0%	100%
Texas	7,686	3%	2%	0%	1%	93%
Utah	430	0%	2%	0%	25%	62%
Vermont	132	0%	0%	0%	100%	0%
Virgin Islands (U.S.)	123	--	--	--	--	--
Virginia	1,748	0%	9%	0%	0%	0%
Washington	2,476	11%	27%	9%	58%	13%
West Virginia	237	2%	35%	1%	6%	56%
Wisconsin	584	1%	7%	0%	43%	57%
Wyoming	75	3%	17%	4%	5%	0%
<b>Total</b>	<b>125,479</b>	<b>9%</b>	<b>12%</b>	<b>8%</b>	<b>20%</b>	<b>64%</b>
<i>Comparison Total<sup>2</sup></i>		<b>88,272</b>	<b>117,564</b>	<b>59,508</b>	<b>100,297</b>	<b>113,095</b>

<sup>1</sup> Eligible for both Medicare and Medicaid.

<sup>2</sup> Comparison Totals are used to calculate the overall category percentages.

Table VI  
ADAP Clients by CD4 Count, Enrolled During 12-Month Period, June 2009

State/Territory	Number of Clients <sup>1</sup>	CD4 ≤200	CD4 between 201-350	CD4 between 351-500	CD4 > 500
Alabama	--	--	--	--	--
Alaska	--	--	--	--	--
American Samoa	--	--	--	--	--
Arizona	--	--	--	--	--
Arkansas	--	--	--	--	--
California	3,605	29%	24%	20%	27%
Colorado	--	--	--	--	--
Connecticut	--	--	--	--	--
Delaware	287	25%	22%	20%	33%
District of Columbia	2,465	19%	20%	21%	40%
Federated States of Micronesia	--	--	--	--	--
Florida	15,569	21%	21%	21%	37%
Georgia	--	--	--	--	--
Guam	3	33%	33%	33%	0%
Hawaii	69	14%	29%	23%	33%
Idaho	58	41%	22%	17%	19%
Illinois	3,865	14%	22%	22%	42%
Indiana	1,462	10%	19%	21%	50%
Iowa	86	33%	26%	20%	22%
Kansas	486	29%	23%	23%	25%
Kentucky	337	37%	26%	15%	21%
Louisiana	--	--	--	--	--
Maine	117	24%	21%	20%	35%
Marshall Islands	--	--	--	--	--
Maryland	1,234	35%	26%	18%	21%
Massachusetts	5,440	27%	22%	20%	30%
Michigan	611	24%	19%	23%	34%
Minnesota	638	21%	24%	21%	34%
Mississippi	--	--	--	--	--
Missouri	--	--	--	--	--
Montana	22	18%	41%	27%	14%
Nebraska	--	--	--	--	--
Nevada	342	35%	22%	18%	25%
New Hampshire	430	15%	17%	22%	46%
New Jersey	7,714	21%	19%	20%	40%
New Mexico	96	25%	18%	24%	33%
New York	18,439	34%	24%	20%	23%
North Carolina	6,064	27%	21%	19%	33%
North Dakota	--	--	--	--	--
Northern Mariana Islands	--	--	--	--	--
Ohio	4,204	18%	20%	20%	42%
Oklahoma	1,004	22%	19%	19%	40%
Oregon	349	24%	25%	26%	25%
Pennsylvania	--	--	--	--	--
Puerto Rico	--	--	--	--	--
Rhode Island	--	--	--	--	--
South Carolina	592	23%	37%	19%	22%
South Dakota	21	24%	19%	33%	24%
Tennessee	755	21%	21%	23%	35%
Texas	2,144	40%	30%	15%	15%
Utah	100	32%	23%	21%	24%
Vermont	--	--	--	--	--
Virgin Islands (U.S.)	42	26%	14%	36%	24%
Virginia	389	33%	25%	19%	24%
Washington	--	--	--	--	--
West Virginia	70	17%	14%	41%	27%
Wisconsin	189	25%	26%	24%	25%
Wyoming	--	--	--	--	--
<b>Total</b>	<b>79,298</b>	<b>26%</b>	<b>22%</b>	<b>20%</b>	<b>32%</b>

<sup>1</sup> This number reflects only the number of clients for which CD4 count was reported.

Table VII  
The National ADAP Budget, by Source, FY2009

State/Territory	Part B ADAP Earmark	% of Total Budget	Part B ADAP Supplemental <sup>1</sup>	% of Total Budget	Part B Base Contribution Directed to ADAP	% of Total Budget	Part B Base Supplemental Directed to ADAP	% of Total Budget
Alabama	\$9,218,808	67%	\$1,742,691	13%	\$303,711	2%	\$0	0%
Alaska	\$577,460	83%	\$109,161	16%	\$0	0%	\$0	0%
American Samoa	\$2,803	100%	--	--	--	--	--	--
Arizona	\$9,658,763	77%	\$1,965,782	16%	\$0	0%	\$0	0%
Arkansas	\$4,174,689	94%	\$0	0%	\$206,092	5%	\$0	0%
California	\$94,104,451	23%	\$0	0%	\$0	0%	\$0	0%
Colorado	\$9,612,191	65%	\$0	0%	\$0	0%	\$0	0%
Connecticut	\$11,550,284	57%	\$0	0%	\$0	0%	\$0	0%
Delaware	\$2,664,690	79%	\$0	0%	\$0	0%	\$0	0%
District of Columbia	\$14,429,241	100%	\$0	0%	\$0	0%	\$0	0%
Federated States of Micronesia	\$7,475	100%	--	--	--	--	--	--
Florida	\$83,621,697	90%	\$0	0%	\$0	0%	\$0	0%
Georgia	\$26,471,603	64%	\$5,004,097	12%	\$56,408	0%	\$0	0%
Guam	\$91,084	100%	\$0	0%	\$0	0%	\$0	0%
Hawaii	\$2,057,066	66%	\$370,229	12%	\$161,995	5%	\$0	0%
Idaho	\$623,246	26%	\$117,816	5%	\$0	0%	\$0	0%
Illinois	\$29,009,556	65%	\$0	0%	\$0	0%	\$1,106,997	2%
Indiana	\$7,634,997	44%	\$1,443,293	8%	\$2,288,086	13%	\$0	0%
Iowa	\$1,447,388	61%	\$273,609	12%	\$74,134	3%	\$0	0%
Kansas	\$2,456,542	35%	\$0	0%	\$0	0%	\$0	0%
Kentucky	\$4,330,107	91%	\$232,000	5%	\$220,000	5%	\$0	0%
Louisiana	\$15,135,021	78%	\$3,615,855	19%	\$0	0%	\$0	0%
Maine	\$866,121	82%	\$0	0%	\$135,633	13%	\$0	0%
Marshall Islands	\$2,968	100%	--	--	--	--	--	--
Maryland	\$27,869,094	66%	\$0	0%	\$0	0%	\$0	0%
Massachusetts	\$14,865,398	77%	\$0	0%	\$0	0%	\$0	0%
Michigan	\$12,219,172	49%	\$0	0%	\$302,696	1%	\$0	0%
Minnesota	\$5,444,759	40%	\$0	0%	\$7,690	0%	\$0	0%
Mississippi	\$7,610,703	100%	--	--	--	--	--	--
Missouri	\$10,102,752	70%	\$0	0%	\$0	0%	\$0	0%
Montana	\$303,681	40%	\$57,409	8%	\$212,469	28%	\$6,601	1%
Nebraska	\$1,367,964	52%	\$258,595	10%	\$53,917	2%	\$0	0%
Nevada	\$6,224,050	91%	\$0	0%	\$132,594	2%	\$0	0%
New Hampshire	\$999,945	33%	\$0	0%	\$0	0%	\$221,613	7%
New Jersey	\$33,279,285	45%	\$0	0%	\$0	0%	\$1,502,256	2%
New Mexico	\$2,243,691	100%	\$0	0%	\$0	0%	\$0	0%
New York	\$126,168,109	49%	\$0	0%	\$1,567,846	1%	\$6,161,038	2%
North Carolina	\$20,117,671	58%	\$3,802,973	11%	\$0	0%	\$0	0%
North Dakota	\$150,440	38%	\$0	0%	\$64,658	16%	\$0	0%
Northern Mariana Islands	\$5,606	100%	--	--	--	--	--	--
Ohio	\$13,805,298	79%	\$0	0%	\$0	0%	\$0	0%
Oklahoma	\$4,290,773	48%	\$811,112	9%	\$1,255,287	14%	\$0	0%
Oregon	\$4,376,738	37%	\$827,363	7%	\$0	0%	\$0	0%
Pennsylvania	\$16,341,059	24%	\$0	0%	\$15,646,059	23%	\$0	0%
Puerto Rico	\$20,854,678	76%	\$3,153,659	12%	\$3,332,017	12%	\$0	0%
Rhode Island	\$2,102,115	43%	\$0	0%	\$0	0%	\$0	0%
South Carolina	\$13,415,102	60%	\$2,507,348	11%	\$0	0%	\$554,279	2%
South Dakota	\$329,844	56%	\$0	0%	\$74,725	13%	\$0	0%
Tennessee	\$12,945,202	52%	\$0	0%	\$0	0%	\$412,609	2%
Texas	\$56,650,912	60%	\$10,709,087	11%	\$0	0%	\$0	0%
Utah	\$2,114,540	43%	\$377,648	8%	\$566,324	11%	\$71,726	1%
Vermont	\$413,006	39%	\$0	0%	\$0	0%	\$0	0%
Virgin Islands (U.S.)	\$517,680	100%	\$0	0%	\$0	0%	\$0	0%
Virginia	\$17,440,610	79%	\$3,296,910	15%	\$0	0%	\$0	0%
Washington	\$9,487,916	35%	\$0	0%	\$155,917	1%	\$0	0%
West Virginia	\$1,374,271	49%	\$0	0%	\$355,029	13%	\$0	0%
Wisconsin	\$4,392,623	40%	\$830,365	8%	\$0	0%	\$0	0%
Wyoming	\$193,421	12%	\$0	0%	\$500,000	30%	\$0	0%
<b>Total</b>	<b>\$779,766,359</b>	<b>49%</b>	<b>\$41,507,002</b>	<b>3%</b>	<b>\$27,673,287</b>	<b>2%</b>	<b>\$10,037,119</b>	<b>1%</b>

<sup>1</sup> Part B ADAP supplemental awards were provided to 21 states that met federal eligibility criteria, applied for funding, and were able to meet the mandated matching requirement or receive a waiver.

	State Contribution	% of Total Budget	Part A Contribution Directed to ADAP	% of Total Budget	Other State or Federal	% of Total Budget	Estimated Drug Rebates	% of Total Budget	Total FY 2009 Budget
	\$2,225,000	16%	\$0	0%	\$0	0%	\$320,000	2%	\$13,810,210
	\$0	0%	\$0	0%	\$0	0%	\$10,000	1%	\$696,621
	--	--	--	--	--	--	--	--	\$2,803
	\$1,000,000	8%	\$0	0%	\$0	0%	\$0	0%	\$12,624,545
	\$0	0%	\$72,794	2%	\$6,000	0.1%	\$0	0%	\$4,459,575
	\$70,849,000	17%	\$0	0%	\$0	0%	\$248,257,000	60%	\$413,210,451
	\$1,357,404	9%	\$0	0%	\$3,707,492	25%	\$0	0%	\$14,677,087
	\$606,678	3%	\$0	0%	\$0	0%	\$8,100,000	40%	\$20,256,962
	\$0	0%	\$0	0%	\$0	0%	\$691,483	20%	\$3,356,173
	\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$14,429,241
	--	--	--	--	--	--	--	--	\$7,475
	\$8,000,000	9%	\$0	0%	\$1,783,044	2%	\$0	0%	\$93,404,741
	\$10,000,000	24%	\$0	0%	\$0	0%	\$0	0%	\$41,532,108
	\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$91,084
	\$440,535	14%	\$0	0%	\$0	0%	\$100,000	3%	\$3,129,825
	\$801,300	33%	\$0	0%	\$0	0%	\$875,000	36%	\$2,417,362
	\$14,504,778	33%	\$0	0%	\$0	0%	\$0	0%	\$44,621,331
	\$0	0%	\$554,112	3%	\$0	0%	\$5,360,000	31%	\$17,280,488
	\$526,078	22%	\$0	0%	\$0	0%	\$34,000	1%	\$2,355,209
	\$500,000	7%	\$0	0%	\$0	0%	\$4,000,000	57%	\$6,956,542
	\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$4,782,107
	\$0	0%	\$0	0%	\$0	0%	\$620,000	3%	\$19,370,876
	\$50,000	5%	\$0	0%	\$0	0%	\$0	0%	\$1,051,754
	--	--	--	--	--	--	--	--	\$2,968
	\$0	0%	\$0	0%	\$110,381	0.3%	\$14,500,000	34%	\$42,479,475
	\$1,893,375	10%	\$1,077,814	6%	\$0	0%	\$1,500,000	8%	\$19,336,587
	\$682,000	3%	\$498,294	2%	\$0	0%	\$11,200,000	45%	\$24,902,162
	\$4,525,577	33%	\$142,000	1%	\$0	0%	\$3,529,075	26%	\$13,649,101
	--	--	--	--	--	--	--	--	\$7,610,703
	\$4,390,000	30%	\$0	0%	\$0	0%	\$4,685	0%	\$14,497,437
	\$171,692	22%	\$0	0%	\$2,453	0.3%	\$10,679	1%	\$764,984
	\$900,000	34%	\$0	0%	\$0	0%	\$54,400	2%	\$2,634,876
		0%	\$0	0%	\$0	0%	\$500,000	7%	\$6,856,644
		0%	\$395,681	13%	\$0	0%	\$1,400,000	46%	\$3,017,239
	\$8,600,000	12%	\$0	0%	\$500	0.001%	\$30,000,000	41%	\$73,382,041
	\$0	0%	\$0	0%	\$0	0%	\$5,000	0%	\$2,248,691
	\$3,302,461	1%	\$8,468,554	3%	\$0	0%	\$111,490,965	43%	\$257,158,973
	\$10,695,504	31%	\$0	0%	\$0	0%	\$0	0%	\$34,616,148
	\$0	0%	\$0	0%	\$0	0%	\$180,000	46%	\$395,098
	--	--	--	--	--	--	--	--	\$5,606
	\$693,100	4%	\$0	0%	\$0	0%	\$3,000,000	17%	\$17,498,398
	\$1,620,000	18%	\$0	0%	\$0	0%	\$900,000	10%	\$8,877,172
	\$1,643,278	14%	\$0	0%	\$135,000	1%	\$4,866,722	41%	\$11,849,101
	\$16,150,699	23%	\$0	0%	\$0	0%	\$21,244,084	31%	\$69,381,901
	\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$27,340,354
	\$1,000,000	20%	\$0	0%	\$0	0%	\$1,800,000	37%	\$4,902,115
	\$2,352,071	11%	\$350,000	2%	\$0	0%	\$3,000,000	14%	\$22,178,800
	\$0	0%	\$0	0%	\$0	0%	\$189,000	32%	\$593,569
	\$7,200,000	29%	\$1,242,442	5%	\$0	0%	\$3,000,000	12%	\$24,800,253
	\$26,887,609	29%	\$0	0%	\$0	0%	\$0	0%	\$94,247,608
	\$94,412	2%	\$0	0%	\$0	0%	\$1,734,542	35%	\$4,959,192
	\$140,000	13%	\$0	0%	\$0	0%	\$500,000	47%	\$1,053,006
	\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$517,680
	\$850,000	4%	\$0	0%	\$6,000	0.03%	\$448,650	2%	\$22,042,170
	\$8,944,861	33%	\$533,457	2%	\$0	0%	\$8,047,200	30%	\$27,169,351
	\$0	0%	\$0	0%	\$0	0%	\$1,100,000	39%	\$2,829,300
	\$926,200	8%	\$0	0%	\$0	0%	\$4,763,723	44%	\$10,912,911
	\$735,000	44%	\$0	0%	\$0	0%	\$240,000	14%	\$1,668,421
	<b>\$215,258,612</b>	<b>14%</b>	<b>\$13,335,148</b>	<b>1%</b>	<b>\$5,750,870</b>	<b>0.4%</b>	<b>\$497,576,208</b>	<b>31%</b>	<b>\$1,590,904,605</b>



Table VIII  
The ADAP Budget, FY2008 and FY2009

State/Territory	ADAP FY2008 Total Budget	ADAP FY2009 Total Budget	% Change
Alabama	\$16,313,574	\$13,810,210	-15%
Alaska	\$674,285	\$696,621	3%
American Samoa	\$1,978	\$2,803	--
Arizona	\$12,723,709	\$12,624,545	-1%
Arkansas	\$4,245,310	\$4,459,575	5%
California	\$321,887,287	\$413,210,451	28%
Colorado	\$14,630,225	\$14,677,087	0%
Connecticut	\$19,578,420	\$20,256,962	3%
Delaware	\$4,415,397	\$3,356,173	-24%
District of Columbia	\$14,392,258	\$14,429,241	0.3%
Federated States of Micronesia	\$4,934	\$7,475	--
Florida	\$94,009,558	\$93,404,741	-1%
Georgia	\$41,731,043	\$41,532,108	-0%
Guam	\$130,055	\$91,084	-30%
Hawaii	\$2,518,601	\$3,129,825	24%
Idaho	\$2,238,972	\$2,417,362	8%
Illinois	\$41,442,223	\$44,621,331	8%
Indiana	\$12,263,515	\$17,280,488	41%
Iowa	\$2,348,431	\$2,355,209	0%
Kansas	\$5,465,222	\$6,956,542	27%
Kentucky	\$6,872,876	\$4,782,107	-30%
Louisiana	\$19,248,508	\$19,370,876	1%
Maine	\$1,088,124	\$1,051,754	-3%
Marshall Islands	\$2,893	\$2,968	--
Maryland	\$72,868,483	\$42,479,475	-42%
Massachusetts	\$19,954,311	\$19,336,587	-3%
Michigan	\$20,681,534	\$24,902,162	20%
Minnesota	\$9,074,912	\$13,649,101	50%
Mississippi	\$7,585,816	\$7,610,703	--
Missouri	\$16,889,193	\$14,497,437	-14%
Montana	\$757,279	\$764,984	1%
Nebraska	\$2,234,366	\$2,634,876	18%
Nevada	\$9,861,493	\$6,856,644	-30%
New Hampshire	\$2,009,571	\$3,017,239	50%
New Jersey	\$69,471,571	\$73,382,041	6%
New Mexico	\$4,060,585	\$2,248,691	-45%
New York	\$260,483,981	\$257,158,973	-1%
North Carolina	\$33,138,757	\$34,616,148	4%
North Dakota	\$439,133	\$395,098	-10%
Northern Mariana Islands	\$3,958	\$5,606	--
Ohio	\$19,999,234	\$17,498,398	-13%
Oklahoma	\$9,361,712	\$8,877,172	-5%
Oregon	\$11,591,911	\$11,849,101	2%
Pennsylvania	\$57,986,902	\$69,381,901	20%
Puerto Rico	\$33,747,827	\$27,340,354	-19%
Rhode Island	\$4,284,014	\$4,902,115	14%
South Carolina	\$25,820,224	\$22,178,800	-14%
South Dakota	\$502,084	\$593,569	18%
Tennessee	\$23,101,925	\$24,800,253	7%
Texas	\$102,703,466	\$94,247,608	-8%
Utah	\$4,339,509	\$4,959,192	14%
Vermont	\$1,002,212	\$1,053,006	5%
Virgin Islands (U.S.)	\$640,973	\$517,680	-19%
Virginia	\$23,977,929	\$22,042,170	-8%
Washington	\$22,197,091	\$27,169,351	22%
West Virginia	\$2,318,538	\$2,829,300	22%
Wisconsin	\$9,792,825	\$10,912,911	11%
Wyoming	\$550,188	\$1,668,421	203%
<b>Total</b>	<b>\$1,521,660,905</b>	<b>\$1,590,904,605</b>	
<b>Comparison Total<sup>1</sup></b>	<b>\$1,514,075,089</b>	<b>\$1,583,293,902</b>	<b>5%</b>

<sup>1</sup> Comparison Totals are based on only those states that reported data for both time periods.

Table IX  
Major FY2009 Budget Categories Compared with FY2008

State/Territory	2008 Part B ADAP Earmark	2009 Part B ADAP Earmark	% Change	2008 Part B ADAP Supplemental <sup>1</sup>	2009 Part B ADAP Supplemental <sup>1</sup>	% Change	2008 Part B Base Contribution Directed to ADAP
Alabama	\$9,055,936	\$9,218,808	2%	\$2,182,235	\$1,742,691	-20.1%	\$0
Alaska	\$508,178	\$577,460	14%	\$124,886	\$109,161	-13%	\$0
American Samoa	\$1,978	\$2,803	42%	--	--	--	--
Arizona	\$9,610,361	\$9,658,763	1%	\$0	\$1,965,782	--	\$0
Arkansas	\$4,245,310	\$4,174,689	-2%	\$0	\$0	--	\$0
California	\$89,623,287	\$94,104,451	4%	\$0	\$0	--	\$0
Colorado	\$9,527,197	\$9,612,191	1%	\$0	\$0	--	\$0
Connecticut	\$11,471,742	\$11,550,284	0.7%	\$0	\$0	--	\$0
Delaware	\$3,291,545	\$2,664,690	-14%	\$0	\$0	--	\$0
District of Columbia	\$14,392,258	\$14,429,241	0.3%	\$0	\$0	--	\$0
Federated States of Micronesia	\$4,934	\$7,475	51%	--	--	--	--
Florida	\$83,509,558	\$83,621,697	0.1%	\$0	\$0	--	\$0
Georgia	\$25,396,411	\$26,471,603	4%	\$5,607,965	\$5,004,097	-11%	\$0
Guam	\$91,055	\$91,084	0%	\$0	\$0	--	\$0
Hawaii	\$2,057,066	\$2,057,066	0%	\$0	\$370,229	--	\$0
Idaho	\$583,136	\$623,246	7%	\$148,418	\$117,816	-20.6%	\$28,118
Illinois	\$27,628,149	\$29,009,556	5%	\$0	\$0	--	\$0
Indiana	\$7,469,885	\$7,634,997	2%	\$1,809,442	\$1,443,293	-20.2%	\$2,324,613
Iowa	\$1,359,141	\$1,447,388	6%	\$335,513	\$273,609	-18%	\$78,777
Kansas	\$2,265,222	\$2,456,542	8%	\$0	\$0	--	\$0
Kentucky	\$4,307,876	\$4,330,107	0.5%	\$0	\$232,000	--	\$65,000
Louisiana	\$15,132,653	\$15,135,021	0%	\$3,615,855	\$3,615,855	0%	\$0
Maine	\$871,574	\$866,121	-0.6%	\$0	\$0	--	\$0
Marshall Islands	\$2,893	\$2,968	3%	--	--	--	--
Maryland	\$26,541,994	\$27,869,094	5%	\$0	\$0	--	\$8,203,661
Massachusetts	\$14,782,288	\$14,865,398	1%	\$0	\$0	--	\$0
Michigan	\$11,681,534	\$12,219,172	5%	\$0	\$0	--	\$0
Minnesota	\$5,143,281	\$5,444,759	6%	\$0	\$0	--	\$3,361
Mississippi	\$7,277,816	\$7,610,703	5%	\$0	--	--	\$100,000
Missouri	\$9,789,559	\$10,102,752	3%	\$0	\$0	--	\$250,000
Montana	\$294,995	\$303,681	3%	\$69,898	\$57,409	-18%	\$232,868
Nebraska	\$1,256,366	\$1,367,964	9%	\$0	\$258,595	--	\$50,000
Nevada	\$5,784,830	\$6,224,050	8%	\$0	\$0	--	\$2,225,402
New Hampshire	\$998,421	\$999,945	0.2%	\$0	\$0	--	\$0
New Jersey	\$33,221,747	\$33,279,285	0.2%	\$0	\$0	--	\$0
New Mexico	\$2,238,552	\$2,243,691	0.2%	\$0	\$0	--	\$1,822,033
New York	\$125,611,598	\$126,168,109	0.4%	\$0	\$0	--	\$856,817
North Carolina	\$18,587,094	\$20,117,671	8%	\$0	\$3,802,973	--	\$0
North Dakota	\$143,526	\$150,440	5%	\$0	\$0	--	\$65,393
Northern Mariana Islands	\$3,958	\$5,606	42%	--	--	--	--
Ohio	\$14,529,892	\$13,805,298	-5%	\$0	\$0	--	\$1,609,342
Oklahoma	\$4,253,231	\$4,290,773	0.9%	\$1,024,714	\$811,112	-20.8%	\$1,477,588
Oregon	\$4,186,545	\$4,376,738	5%	\$1,028,209	\$827,363	-19.5%	\$0
Pennsylvania	\$28,159,902	\$16,341,059	-42%	\$0	\$0	--	\$0
Puerto Rico	\$20,674,920	\$20,854,678	0.9%	\$1,612,384	\$3,153,659	96%	\$3,403,393
Rhode Island	\$2,002,014	\$2,102,115	5%	\$0	\$0	--	\$0
South Carolina	\$13,399,717	\$13,415,102	0.1%	\$3,120,507	\$2,507,348	-20%	\$0
South Dakota	\$305,924	\$329,844	8%	\$0	\$0	--	\$80,000
Tennessee	\$12,597,325	\$12,945,202	3%	\$0	\$0	--	\$0
Texas	\$53,842,575	\$56,650,912	5%	\$13,385,584	\$10,709,087	-20%	\$0
Utah	\$2,109,364	\$2,114,540	0.2%	\$474,379	\$377,648	-20%	\$698,840
Vermont	\$402,212	\$413,006	3%	\$0	\$0	--	\$0
Virgin Islands (U.S.)	\$640,973	\$517,680	-38%	\$0	\$0	--	\$0
Virginia	\$16,730,761	\$17,440,610	4%	\$4,134,968	\$3,296,910	-20%	\$0
Washington	\$8,694,418	\$9,487,916	9%	\$0	\$0	--	\$0
West Virginia	\$1,373,538	\$1,374,271	0.1%	\$0	\$0	--	\$0
Wisconsin	\$4,290,852	\$4,392,623	2%	\$1,043,819	\$830,365	-20%	\$0
Wyoming	\$180,188	\$193,421	7%	\$0	\$0	--	\$270,000
<b>Total</b>	<b>\$774,139,255</b>	<b>\$779,766,359</b>	<b>0.58%</b>	<b>\$39,718,776</b>	<b>\$41,507,002</b>	<b>5%</b>	<b>\$23,845,206</b>

<sup>1</sup> Part B ADAP Supplemental awards were provided to states that met federal eligibility criteria, applied for funding, and were able to meet the mandated matching requirement or receive a waiver.

2009 Part B Base Contribution Directed to ADAP	% Change	2008 State Contribution	2009 State Contribution	% Change	2008 Part A Contribution Directed to ADAP	2009 Part A Contribution Directed to ADAP	% Change	2008 Estimated Drug Rebates	2009 Estimated Drug Rebates	% Change
\$303,711	--	\$5,075,403	\$2,225,000	-56%	\$0	\$0	--	\$0	\$320,000	--
\$0	--	\$31,221	\$0	-100%	\$0	\$0	--	\$10,000	\$10,000	0%
--	--	--	--	--	\$0	--	--	--	--	--
\$0	--	\$1,000,000	\$1,000,000	0%	\$327,000	\$0	-100%	\$0	\$0	--
\$206,092	--	\$0	\$0	--	\$0	\$72,794	--	\$0	\$0	--
\$0	--	\$96,349,000	\$70,849,000	-26%	\$0	\$0	--	\$135,915,000	\$248,257,000	83%
\$0	--	\$5,083,028	\$1,357,404	-73%	\$0	\$0	--	\$20,000	\$0	-100%
\$0	--	\$606,678	\$606,678	0%	\$0	\$0	--	\$7,500,000	\$8,100,000	8%
\$0	--	\$0	\$0	--	\$0	\$0	--	\$281,775	\$691,483	145%
\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
--	--	--	--	--	\$0	--	--	--	--	--
\$0	--	\$10,500,000	\$8,000,000	-24%	\$0	\$0	--	\$0	\$0	--
\$56,408	--	\$9,500,000	\$10,000,000	5%	\$0	\$0	--	\$0	\$0	--
\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
\$161,995	--	\$440,535	\$440,535	0%	\$0	\$0	--	\$21,000	\$100,000	376%
\$0	-100%	\$779,300	\$801,300	3%	\$0	\$0	--	\$700,000	\$875,000	25%
\$0	--	\$13,814,074	\$14,504,778	5%	\$0	\$0	--	\$0	\$0	--
\$2,288,086	-2%	\$0	\$0	--	\$454,575	\$554,112	22%	\$205,000	\$5,360,000	2515%
\$74,134	-6%	\$555,000	\$526,078	-5%	\$0	\$0	--	\$20,000	\$34,000	70%
\$0	--	\$0	\$500,000	--	\$0	\$0	--	\$3,200,000	\$4,000,000	25%
\$220,000	238%	\$0	\$0	--	\$0	\$0	--	\$2,500,000	\$0	-100%
\$0	--	\$0	\$0	--	\$0	\$0	--	\$500,000	\$620,000	24%
\$135,633	--	\$66,550	\$50,000	-25%	\$0	\$0	--	\$150,000	\$0	-100%
--	--	--	--	--	\$0	--	--	--	--	--
\$0	-100%	\$17,372,828	\$0	-100%	\$0	\$0	--	\$20,000,000	\$14,500,000	-28%
\$0	--	\$1,958,523	\$1,893,375	-3%	\$1,713,500	\$1,077,814	-37%	\$1,500,000	\$1,500,000	0%
\$302,696	--	\$0	\$682,000	--	\$0	\$498,294	--	\$9,000,000	\$11,200,000	24%
\$7,690	129%	\$0	\$4,525,577	--	\$0	\$142,000	--	\$3,928,270	\$3,529,075	-10%
--	--	\$0	--	--	\$0	--	--	\$208,000	--	--
\$0	-100%	\$3,649,634	\$4,390,000	20%	\$0	\$0	--	\$3,200,000	\$4,685	-100%
\$212,469	-9%	\$147,018	\$171,692	17%	\$0	\$0	--	\$12,500	\$10,679	-15%
\$53,917	8%	\$900,000	\$900,000	0%	\$0	\$0	--	\$28,000	\$54,400	94%
\$132,594	-94%	\$1,633,261	\$0	-100%	\$0	\$0	--	\$110,000	\$500,000	355%
\$0	--	\$500,000	\$0	-100%	\$411,150	\$395,681	-4%	\$100,000	\$1,400,000	1300%
\$0	--	\$4,700,000	\$8,600,000	83%	\$0	\$0	--	\$31,549,324	\$30,000,000	-5%
\$0	-100%	\$0	\$0	--	\$0	\$0	--	\$0	\$5,000	--
\$1,567,846	83%	\$55,000,000	\$3,302,461	-94%	\$9,670,966	\$8,468,554	-12%	\$69,344,600	\$111,490,965	61%
\$0	--	\$14,551,663	\$10,695,504	-26%	\$0	\$0	--	\$0	\$0	--
\$64,658	-1%	\$0	\$0	--	\$0	\$0	--	\$150,000	\$180,000	20%
--	--	--	--	--	\$0	--	--	--	--	--
\$0	-100%	\$3,000,000	\$693,100	-77%	\$0	\$0	--	\$250,000	\$3,000,000	1100%
\$1,255,287	-15%	\$1,646,179	\$1,620,000	-2%	\$0	\$0	--	\$960,000	\$900,000	-6%
\$0	--	\$1,157,157	\$1,643,278	42%	\$0	\$0	--	\$5,076,000	\$4,866,722	-4%
\$15,646,059	--	\$16,267,000	\$16,150,699	-0.7%	\$0	\$0	--	\$13,560,000	\$21,244,084	57%
\$3,332,017	-2%	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
\$0	--	\$1,700,000	\$1,000,000	-41%	\$0	\$0	--	\$582,000	\$1,800,000	209%
\$0	--	\$5,900,000	\$2,352,071	-60%	\$0	\$350,000	--	\$3,400,000	\$3,000,000	-12%
\$74,725	-7%	\$0	\$0	--	\$0	\$0	--	\$116,160	\$189,000	63%
\$0	--	\$7,300,000	\$7,200,000	-1%	\$1,704,600	\$1,242,442	-27%	\$1,500,000	\$3,000,000	100%
\$0	--	\$35,475,307	\$26,887,609	-24%	\$0	\$0	--	\$0	\$0	--
\$566,324	-19%	\$0	\$94,412	--	\$0	\$0	--	\$1,056,926	\$1,734,542	64%
\$0	--	\$0	\$140,000	--	\$0	\$0	--	\$600,000	\$500,000	-17%
\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
\$0	--	\$2,612,200	\$850,000	-67%	\$0	\$0	--	\$500,000	\$448,650	-10%
\$155,917	-	\$8,809,064	\$8,944,861	2%	\$383,063	\$533,457	39%	\$4,310,546	\$8,047,200	87%
\$355,029	--	\$0	\$0	--	\$0	\$0	--	\$945,000	\$1,100,000	16%
\$0	--	\$464,000	\$926,200	100%	\$0	\$0	--	\$3,994,154	\$4,763,723	19%
\$500,000	85%	\$0	\$735,000	--	\$0	\$0	--	\$100,000	\$240,000	140%
<b>\$27,673,287</b>	<b>16%</b>	<b>\$328,544,623</b>	<b>\$215,258,612</b>	<b>-34%</b>	<b>\$14,664,854</b>	<b>\$13,335,148</b>	<b>-9%</b>	<b>\$327,104,255</b>	<b>\$497,576,208</b>	<b>52%</b>

Table X

## Cost Recovery and Other Cost-Saving Mechanisms (Excluding Drug Rebates), FY2009

State/Territory	Private Insurance	Medicaid	Manufacturers' Free Product	Other	Total
Alabama	\$0	\$80,000	\$0	\$0	\$80,000
Alaska	\$620,000	\$0	\$0	\$0	\$620,000
American Samoa	--	--	--	--	\$0
Arizona	\$0	\$0	\$0	\$0	\$0
Arkansas	\$0	\$0	\$0	\$0	\$0
California	\$0	\$0	\$0	\$0	\$0
Colorado	\$0	\$314,556	\$0	\$0	\$314,556
Connecticut	\$0	\$776,173	\$0	\$0	\$776,173
Delaware	\$0	\$0	\$0	\$0	\$0
District of Columbia	\$0	\$0	\$0	\$0	\$0
Federated States of Micronesia	--	--	--	--	\$0
Florida	\$0	\$0	\$0	\$0	\$0
Georgia	\$0	\$0	\$0	\$0	\$0
Guam	\$0	\$0	\$0	\$0	\$0
Hawaii	\$0	\$0	\$0	\$0	\$0
Idaho	\$0	\$0	\$0	\$0	\$0
Illinois	\$0	\$0	\$0	\$0	\$0
Indiana	\$0	\$0	\$0	\$0	\$0
Iowa	\$115,255	\$12,000	\$0	\$0	\$127,255
Kansas	\$0	\$0	\$0	\$0	\$0
Kentucky	\$0	\$0	\$0	\$0	\$0
Louisiana	\$0	\$0	\$0	\$0	\$0
Maine	\$800	\$0	\$0	\$0	\$800
Marshall Islands	--	--	--	--	\$0
Maryland	\$0	\$0	\$0	\$0	\$0
Massachusetts	\$0	\$0	\$0	\$0	\$0
Michigan	\$0	\$0	\$0	\$0	\$0
Minnesota	\$0	\$0	\$0	\$0	\$0
Mississippi	--	--	--	--	\$0
Missouri	\$105,000	\$2,000,000	\$0	\$0	\$2,105,000
Montana	\$0	\$0	\$0	\$0	\$0
Nebraska	\$0	\$0	\$0	\$0	\$0
Nevada	\$0	\$0	\$0	\$0	\$0
New Hampshire	\$0	\$0	\$0	\$0	\$0
New Jersey	\$7,100,000	\$3,236,578	\$0	\$0	\$10,336,578
New Mexico	\$0	\$0	\$0	\$5,000,000	\$5,000,000
New York	\$26,596,552	\$1,000,000	\$0	\$0	\$27,596,552
North Carolina	\$0	\$0	\$178,185	\$795,136	\$973,321
North Dakota	\$0	\$0	\$0	\$0	\$0
Northern Mariana Islands	--	--	--	--	\$0
Ohio	\$0	\$0	\$0	\$0	\$0
Oklahoma	\$120,000	\$70,000	\$0	\$0	\$190,000
Oregon	\$0	\$0	\$0	\$0	\$0
Pennsylvania	\$0	\$0	\$0	\$0	\$0
Puerto Rico	\$0	\$6,582,161	\$0	\$0	\$6,582,161
Rhode Island	\$0	\$0	\$0	\$0	\$0
South Carolina	\$0	\$0	\$0	\$0	\$0
South Dakota	\$0	\$0	\$0	\$0	\$0
Tennessee	\$0	\$0	\$0	\$0	\$0
Texas	\$0	\$0	\$0	\$0	\$0
Utah	\$0	\$100,000	\$0	\$0	\$100,000
Vermont	\$0	\$0	\$0	\$0	\$0
Virgin Islands (U.S.)	\$0	\$0	\$0	\$0	\$0
Virginia	\$0	\$321,327	\$0	\$0	\$321,327
Washington	\$3,567	\$334,000	\$0	\$0	\$337,567
West Virginia	\$0	\$0	\$0	\$0	\$0
Wisconsin	\$69,090	\$422,517	\$0	\$0	\$491,607
Wyoming	\$0	\$0	\$0	\$0	\$0
<b>Totals</b>	<b>\$34,730,264</b>	<b>\$15,249,312</b>	<b>\$178,185</b>	<b>\$5,795,136</b>	<b>\$55,952,897</b>
<b>Total # of ADAPs</b>	<b>9</b>	<b>13</b>	<b>1</b>	<b>2</b>	<b>17</b>

Table XI  
ADAP Drug Expenditures (Including Drug Purchases and Co-Payments), June 2009

State/Territory	June 2009 Drug Purchases	Drug Purchases % of Total Expenditures	June 2009 Co-Payment Expenditures	Co-Payment % of Total Expenditures	June 2009 Total Drug Expenditures
Alabama	\$1,484,321	100%	\$12	0%	\$1,484,333
Alaska	\$88,957	100%	\$0	0%	\$88,957
American Samoa	--	--	--	--	\$0
Arizona	\$1,179,812	100%	\$0	0%	\$1,179,812
Arkansas	\$396,767	95%	\$20,569	5%	\$417,336
California	\$32,060,460	100%	\$0	0%	\$32,060,460
Colorado	\$1,006,183	100%	\$0	0%	\$1,006,183
Connecticut	\$1,806,598	100%	\$0	0%	\$1,806,598
Delaware	\$185,144	100%	\$0	0%	\$185,144
District of Columbia	\$1,441,644	100%	\$0	0%	\$1,441,644
Federated States of Micronesia	--	--	--	--	\$0
Florida	\$5,747,226	100%	\$0	0%	\$5,747,226
Georgia	\$3,849,672	100%	\$0	0%	\$3,849,672
Guam	\$8,090	100%	\$0	0%	\$8,090
Hawaii	\$205,059	98%	\$4,405	2%	\$209,464
Idaho	\$216,444	100%	\$0	0%	\$216,444
Illinois	\$3,587,159	99%	\$41,541	1%	\$3,628,700
Indiana	\$106,323	43%	\$138,643	57%	\$244,966
Iowa	\$242,930	90%	\$26,015	10%	\$268,944
Kansas	\$634,242	100%	\$0	0%	\$634,242
Kentucky	\$710,963	92%	\$62,691	8%	\$773,654
Louisiana	\$2,038,551	100%	\$0	0%	\$2,038,551
Maine	\$43,031	84%	\$8,179	16%	\$51,210
Marshall Islands	--	--	--	--	\$0
Maryland	\$2,444,882	100%	\$0	0%	\$2,444,882
Massachusetts	\$206,946	57%	\$155,284	43%	\$362,229
Michigan	\$1,904,570	100%	\$0	0%	\$1,904,570
Minnesota	\$318,218	100%	\$0	0%	\$318,218
Mississippi	--	--	--	--	--
Missouri	\$1,775,622	100%	\$124,474	0%	\$1,900,096
Montana	\$60,135	96%	\$2,448	4%	\$62,583
Nebraska	\$170,054	93%	\$12,547	7%	\$182,601
Nevada	\$645,518	96%	\$28,849	4%	\$674,367
New Hampshire	\$157,046	86%	\$25,972	14%	\$183,018
New Jersey	\$7,322,639	100%	\$0	0%	\$7,322,639
New Mexico	\$31,485	100%	\$0	0%	\$31,485
New York	\$22,923,977	100%	\$0	0%	\$22,923,977
North Carolina	\$3,328,129	92%	\$289,894	8%	\$3,618,023
North Dakota	\$42,900	100%	\$0	0%	\$42,900
Northern Mariana Islands	--	--	--	--	--
Ohio	\$328,349	76%	\$104,925	24%	\$433,274
Oklahoma	\$627,683	91%	\$60,553	9%	\$688,236
Oregon	\$217,047	100%	\$0	0%	\$217,047
Pennsylvania	\$4,807,876	100%	\$0	0%	\$4,807,876
Puerto Rico	\$3,014,978	100%	\$0	0%	\$3,014,978
Rhode Island	\$397,790	100%	\$0	0%	\$397,790
South Carolina	\$1,989,182	94%	\$135,566	6%	\$2,124,748
South Dakota	\$84,310	100%	\$0	0%	\$84,310
Tennessee	\$1,526,669	100%	\$0	0%	\$1,526,669
Texas	\$7,351,624	100%	\$0	0%	\$7,351,624
Utah	\$308,957	87%	\$46,745	13%	\$355,702
Vermont	\$65,803	100%	\$0	0%	\$65,803
Virgin Islands (U.S.)	--	--	--	--	--
Virginia	\$3,390,451	100%	\$0	0%	\$3,390,451
Washington	\$914,345	92%	\$82,198	8%	\$996,543
West Virginia	\$259,027	100%	\$0	0%	\$259,027
Wisconsin	\$710,988	100%	\$0	0%	\$710,988
Wyoming	\$100,021	100%	\$0	0%	\$100,021
<b>Total</b>	<b>\$124,466,798</b>	<b>99%</b>	<b>\$1,371,508</b>	<b>1%</b>	<b>\$125,838,306</b>

Table XII

## ADAP Prescriptions Filled (Including Drug Purchases and Co-Payments), June 2009

State/Territory	June 2009 Drug Purchases Rx <sup>1</sup>	Drug Purchases Rx % of Total Rx	June 2009 Co-Payment Rx	Co-Payment Rx % of Total Rx	June 2009 Total Rx
Alabama	4,635	100%	2	0%	4,637
Alaska	232	100%	0	0%	232
American Samoa	--	--	--	--	--
Arizona	4,234	100%	0	0%	4,234
Arkansas	1,378	77%	408	23%	1,786
California	92,769	100%	0	0%	92,769
Colorado	3,472	100%	0	0%	3,472
Connecticut	5,073	100%	0	0%	5,073
Delaware	2,011	100%	0	0%	2,011
District of Columbia	3,859	100%	0	0%	3,859
Federated States of Micronesia	--	--	--	--	--
Florida	27,992	100%	0	0%	27,992
Georgia	11,917	100%	0	0%	11,917
Guam	18	100%	0	0%	18
Hawaii	636	94%	43	6%	679
Idaho	290	100%	0	0%	290
Illinois	9,493	94%	563	6%	10,056
Indiana	253	3%	7,134	97%	7,387
Iowa	612	65%	324	35%	936
Kansas	1,253	100%	0	0%	1,253
Kentucky	2,003	56%	1,568	44%	3,571
Louisiana	2,488	100%	0	0%	2,488
Maine	81	14%	519	87%	600
Marshall Islands	--	--	--	--	--
Maryland	10,156	100%	0	0%	10,156
Massachusetts	681	6%	10,109	94%	10,790
Michigan	7,526	100%	0	0%	7,526
Minnesota	1,243	100%	0	0%	1,243
Mississippi	--	--	--	--	--
Missouri	3,629	100%	1,651	0%	5,280
Montana	142	84%	27	16%	169
Nebraska	439	70%	191	30%	630
Nevada	1,561	83%	324	17%	1,885
New Hampshire	322	34%	614	66%	936
New Jersey	22,576	100%	0	0%	22,576
New Mexico	98	100%	0	0%	98
New York	68,412	100%	0	0%	68,412
North Carolina	13,420	94%	905	6%	14,325
North Dakota	104	100%	0	0%	104
Northern Mariana Islands	--	--	--	--	--
Ohio	4,727	73%	1,785	27%	6,512
Oklahoma	2,088	73%	769	27%	2,857
Oregon	6,273	100%	0	0%	6,273
Pennsylvania	14,498	100%	0	0%	14,498
Puerto Rico	9,736	100%	0	0%	9,736
Rhode Island	1,096	100%	0	0%	1,096
South Carolina	5,483	71%	2,255	29%	7,738
South Dakota	223	100%	0	0%	223
Tennessee	3,943	100%	0	0%	3,943
Texas	18,244	100%	0	0%	18,244
Utah	972	69%	431	31%	1,403
Vermont	308	100%	0	0%	308
Virgin Islands (U.S.)	--	--	--	--	--
Virginia	5,304	100%	0	0%	5,304
Washington	4,497	69%	2,004	31%	6,501
West Virginia	685	100%	0	0%	685
Wisconsin	1,625	100%	0	0%	1,625
Wyoming	254	100%	0	0%	254
<b>Total</b>	<b>384,964</b>	<b>92%</b>	<b>31,626</b>	<b>8%</b>	<b>416,590</b>

<sup>1</sup> Rx=Prescription

Table XIII  
ADAP Drug Expenditures, by Drug Class, June 2009

State/Territory	June 2009 Total Expenditures	June 2009 ARV Total Expenditures <sup>1</sup>	ARV % of Total Expenditures <sup>1</sup>	June 2009 "A1" OI Total Expenditures <sup>2</sup>	"A1" OI % of Total Expenditures <sup>2</sup>	June 2009 All Other Total Expenditures	All Other % of Total Expenditures
Alabama	\$1,484,333	\$1,418,999	96%	\$36,325	2%	\$29,009	2%
Alaska	\$88,957	\$84,176	95%	\$108	0.1%	\$4,673	5%
American Samoa	--	--	--	--	--	--	--
Arizona	\$1,179,812	\$1,089,468	92%	\$20,771	2%	\$69,573	6%
Arkansas	\$417,336	\$383,276	92%	\$8,163	2%	\$25,867	6%
California	\$32,060,460	\$28,853,249	90%	\$876,949	3%	\$2,330,263	7%
Colorado	\$1,006,183	\$958,480	95%	\$13,891	1%	\$33,812	3%
Connecticut	\$1,806,598	\$1,430,090	79%	\$12,484	1%	\$364,024	20%
Delaware	\$185,144	\$154,523	83%	\$1,213	1%	\$29,409	16%
District of Columbia	\$1,441,644	\$1,150,190	80%	\$291,265	20%	\$189	0.01%
Federated States of Micronesia	--	--	--	--	--	--	--
Florida	\$5,747,226	\$5,322,947	93%	\$48,800	1%	\$375,479	7%
Georgia	\$3,849,672	\$3,693,319	96%	\$117,466	3%	\$38,887	1%
Guam	\$8,090	\$6,998	87%	\$1,092	13%	\$0	0%
Hawaii	\$209,464	\$194,005	93%	\$3,685	2%	\$11,774	6%
Idaho	\$216,444	\$215,863	100%	\$581	0.3%	\$0	0%
Illinois	\$3,628,700	\$3,485,948	96%	\$62,616	2%	\$80,136	2%
Indiana	\$244,966	\$139,944	57%	\$5,265	2%	\$99,758	41%
Iowa	\$268,944	\$261,918	97%	\$6,319	2%	\$708	0.3%
Kansas	\$634,242	\$593,466	94%	\$8,867	1%	\$31,910	5%
Kentucky	\$773,654	\$744,819	96%	\$10,684	1%	\$18,151	2%
Louisiana	\$2,038,551	\$2,016,252	99%	\$14,854	1%	\$7,445	0.4%
Maine	\$51,210	\$47,222	92%	\$478	1%	\$3,060	6%
Marshall Islands	--	--	--	--	--	--	--
Maryland	\$2,444,882	\$2,289,119	94%	\$40,640	2%	\$115,123	5%
Massachusetts	\$362,229	\$290,578	80%	\$10,669	3%	\$60,982	17%
Michigan	\$1,904,570	\$1,779,871	93%	\$8,845	0.5%	\$115,854	6%
Minnesota	\$318,218	\$316,364	99%	\$1,669	1%	\$186	0.1%
Mississippi	--	--	--	--	--	--	--
Missouri	\$1,900,096	\$1,734,247	91%	\$47,194	2%	\$118,655	6%
Montana	\$62,583	\$62,415	100%	\$78	0.1%	\$90	0.1%
Nebraska	\$182,601	\$178,798	98%	\$1,601	1%	\$2,202	1%
Nevada <sup>3</sup>	\$674,367	\$674,367	100%	\$0	0%	\$0	0%
New Hampshire	\$183,018	\$159,979	87%	\$1,194	0.7%	\$21,845	12%
New Jersey	\$7,322,639	\$5,531,232	76%	\$133,695	2%	\$1,657,712	23%
New Mexico	\$31,485	\$30,559	97%	\$3	0.01%	\$923	3%
New York	\$22,923,977	\$20,244,358	88%	\$586,740	3%	\$2,092,879	9%
North Carolina	\$3,618,023	\$3,139,251	87%	\$96,825	3%	\$381,947	11%
North Dakota	\$42,900	\$42,483	99%	\$171	0.4%	\$246	1%
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	\$433,274	\$346,228	80%	\$24,608	6%	\$62,438	14%
Oklahoma	\$688,236	\$656,036	95%	\$6,504	1%	\$25,695	4%
Oregon	\$217,047	\$157,425	73%	\$3,751	2%	\$55,871	26%
Pennsylvania	\$4,807,876	\$4,367,989	91%	\$94,690	2%	\$345,197	7%
Puerto Rico	\$3,014,978	\$3,012,907	100%	\$2,072	0.1%	\$0	0%
Rhode Island	\$397,790	\$377,681	95%	\$11,850	3%	\$8,259	2%
South Carolina	\$2,124,748	\$2,066,900	97%	\$14,323	1%	\$43,524	2%
South Dakota	\$84,310	\$80,294	95%	\$593	1%	\$3,423	4%
Tennessee	\$1,526,669	\$1,447,865	95%	\$49,276	3%	\$29,528	2%
Texas	\$7,351,624	\$7,263,516	99%	\$48,470	1%	\$39,638	0.5%
Utah	\$355,702	\$344,797	97%	\$4,111	1%	\$6,794	2%
Vermont	\$65,803	\$65,803	100%	\$0	0%	\$0	0%
Virgin Islands (U.S.)	--	--	--	--	--	--	--
Virginia	\$3,390,451	\$3,275,734	97%	\$56,937	2%	\$57,780	2%
Washington	\$996,543	\$927,630	93%	\$11,758	1%	\$57,155	6%
West Virginia	\$259,027	\$248,666	96%	\$3,885	1%	\$6,476	3%
Wisconsin	\$710,988	\$673,585	95%	\$28,989	4%	\$8,414	1%
Wyoming	\$100,021	\$95,234	95%	\$833	0.8%	\$3,954	4%
<b>Total</b>	<b>\$125,838,306</b>	<b>\$114,127,058</b>	<b>91%</b>	<b>\$2,833,851</b>	<b>2%</b>	<b>\$8,876,917</b>	<b>7%</b>

<sup>1</sup> ARV=Antiretrovirals.

<sup>2</sup> "A1" OI=Drugs recommended ("A1") for the prevention and treatment of opportunistic infections (OIs).

<sup>3</sup> Nevada was unable to separate ARVs from all other medications. All drug expenditures are included as ARVs.

Table XIV

## ADAP Prescriptions Filled, by Drug Class, June 2009

State/Territory	June 2009 Total Rx <sup>1</sup>	June 2009 ARV Total Rx <sup>2</sup>	ARV % of Total Rx <sup>2</sup>	June 2009 "A1" OI Total Rx <sup>3</sup>	"A1" OI % of Total Rx <sup>3</sup>	June 2009 All Other Total Rx	All Other Rx % of Total Rx
Alabama	4,637	3,143	68%	851	18%	643	14%
Alaska	232	150	65%	48	21%	34	15%
American Samoa	--	--	--	--	--	--	--
Arizona	4,234	2,611	62%	343	8%	1,280	30%
Arkansas	1,786	954	53%	304	17%	528	30%
California	92,769	53,000	57%	9,750	11%	30,019	32%
Colorado	3,472	2,208	64%	382	11%	882	25%
Connecticut	5,073	2,694	53%	91	2%	2,288	45%
Delaware	2,011	858	43%	113	6%	1,040	52%
District of Columbia	3,859	2,781	72%	1,036	27%	42	1%
Federated States of Micronesia	--	--	--	--	--	--	--
Florida	27,992	21,376	76%	2,368	8%	4,248	15%
Georgia	11,917	9,471	79%	2,211	19%	235	2%
Guam	18	10	56%	8	44%	0	0%
Hawaii	679	490	72%	72	11%	147	22%
Idaho	290	253	87%	37	13%	0	0%
Illinois	10,056	8,073	80%	734	7%	1,249	12%
Indiana	7,387	1,853	25%	281	4%	5,253	71%
Iowa	936	807	86%	70	7%	59	6%
Kansas	1,253	943	75%	220	18%	90	7%
Kentucky	3,571	2,622	73%	361	10%	588	16%
Louisiana	2,488	1,729	69%	697	28%	62	2%
Maine	600	321	54%	43	7%	236	39%
Marshall Islands	--	--	--	--	--	--	--
Maryland	10,156	6,453	64%	472	5%	3,231	32%
Massachusetts	10,790	4,050	38%	414	4%	6,326	59%
Michigan	7,526	3,977	53%	402	5%	3,147	42%
Minnesota	1,243	1,133	91%	33	3%	77	6%
Mississippi	--	--	--	--	--	--	--
Missouri	5,280	2,771	52%	359	7%	2,150	41%
Montana	169	155	92%	5	3%	9	5%
Nebraska	630	468	74%	55	9%	107	17%
Nevada <sup>4</sup>	1,885	1,885	100%	0	0%	0	0%
New Hampshire	936	396	42%	12	1%	528	56%
New Jersey	22,576	8,531	38%	1,383	6%	12,662	56%
New Mexico	98	72	73%	2	2%	24	24%
New York	68,412	29,733	43%	4,476	7%	34,203	50%
North Carolina	14,325	6,808	48%	1,814	13%	5,703	40%
North Dakota	104	86	83%	10	10%	8	8%
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	6,512	3,402	52%	115	2%	2,995	46%
Oklahoma	2,857	1,757	61%	306	11%	794	28%
Oregon	6,273	2,395	38%	348	6%	3,530	56%
Pennsylvania	14,498	7,310	50%	944	7%	6,244	43%
Puerto Rico	9,736	9,726	100%	13	0.1%	0	0%
Rhode Island	1,096	814	74%	100	9%	182	17%
South Carolina	7,738	6,112	79%	435	6%	1,191	15%
South Dakota	223	165	74%	22	10%	36	16%
Tennessee	3,943	2,493	63%	662	17%	788	20%
Texas	18,244	17,907	98%	863	5%	284	2%
Utah	1,403	973	69%	106	8%	324	23%
Vermont	308	308	100%	0	0%	0	0%
Virgin Islands (U.S.)	--	--	--	--	--	--	--
Virginia	5,304	3,762	71%	718	14%	824	16%
Washington	6,501	3,410	52%	634	10%	2,457	38%
West Virginia	685	493	72%	69	10%	123	18%
Wisconsin	1,625	1,258	77%	224	14%	143	9%
Wyoming	254	121	48%	27	11%	106	42%
<b>Total</b>	<b>416,590</b>	<b>245,271</b>	<b>59%</b>	<b>35,043</b>	<b>8%</b>	<b>137,119</b>	<b>33%</b>

<sup>1</sup> Rx=Prescription.<sup>2</sup> ARV=Antiretrovirals.<sup>3</sup> "A1" OI=Drugs recommended ("A1") for the prevention and treatment of opportunistic infections (OIs).<sup>4</sup> Nevada was unable to separate ARVs from all other medications. All prescriptions filled are included as ARVs.

Table XV - Federal ADAP Funds Used For and Number of Clients Served Through Insurance Purchasing/Maintenance, 2009

State/Territory <sup>1</sup>	FY2009 Est. Expenditures	June 2009 Expenditures	June 2009 Clients Served
Alabama	\$90,000	\$3,314	56
Alaska	\$216,000	\$18,000	31
American Samoa	--	--	--
Arizona	--	--	--
<b>Arkansas</b>	\$520,000	\$4,848	88
California	\$47,000,000	\$1,254,458	8,003
Colorado	\$2,833,000	\$213,227	466
<b>Connecticut</b>	\$500,000	\$0	--
Delaware	--	\$6,649	10
District of Columbia	\$540,000	\$46,447	249
Federated States of Micronesia	--	--	--
Florida	\$4,000,000	\$131,839	576
Georgia	\$1,500,000	\$112,500	300
Guam	--	--	--
Hawaii	\$260,000	\$18,625	51
Idaho	--	--	--
Illinois	\$0	\$41,542	214
Indiana	\$15,946,152	\$299,344	1,360
Iowa	\$170,000	\$45,175	117
Kansas	\$150,000	\$14,705	263
Kentucky	\$1,163,396	\$62,691	--
Louisiana	\$300,000	\$22,529	112
Maine	\$275,000	\$22,887	165
Marshall Islands	--	--	--
Maryland	\$5,000,000	\$663,971	1,248
Massachusetts	\$10,000,000	\$815,523	3,807
Michigan	\$1,017,000	\$76,549	645
Minnesota	\$2,931,027	\$201,699	785
Mississippi	--	--	--
Missouri	\$1,000,000	\$116,201	437
Montana	\$48,000	\$2,448	11
Nebraska	\$150,000	\$16,000	74
Nevada	\$343,149	\$42,092	278
New Hampshire	--	--	134
New Jersey	\$3,200,000	\$282,201	80
New Mexico	\$1,885,279	\$191,227	578
New York	\$17,000,000	\$1,789,856	2,066
<b>North Carolina</b>	\$2,000,000	\$289,894	322
North Dakota	--	--	--
Northern Mariana Islands	--	--	--
Ohio	\$1,520,425	\$377,943	1,234
Oklahoma	\$1,681,615	\$117,063	322
Oregon	\$2,427,962	\$710,777	702
<b>Pennsylvania</b>	\$300,000	\$13,683	1,595
<b>Puerto Rico</b>	\$1,744,648	\$0	--
<b>Rhode Island</b>	\$166,184	\$8,942	41
South Carolina	\$1,962,000	\$171,111	434
South Dakota	--	--	--
Tennessee	\$8,600,000	\$650,505	1,169
<b>Texas</b>	\$2,427,962	\$710,777	702
Utah	\$490,000	\$99,435	115
Vermont	\$413,006	\$65,803	132
Virgin Islands (U.S.)	--	--	--
Virginia	--	--	--
Washington	\$14,750,000	\$500,476	1,816
<b>West Virginia</b>	\$167,500	\$10,537	--
Wisconsin	\$5,064,615	\$604,007	503
Wyoming	--	--	--
<b>Total</b>	<b>\$161,753,920</b>	<b>\$10,847,500</b>	<b>31,291</b>

<sup>1</sup> New states since 2008 reported in bold.

Table XVI  
ADAP Client Eligibility Requirements, June 30, 2009

State/Territory	Financial Eligibility as % of FPL <sup>1</sup>	Medical Eligibility <sup>2</sup>	Asset Limits	State Residency Requirement	Other Requirement
Alabama	250% GR	--	--	Yes (Proof required)	--
Alaska	300% GR	--	Yes	Yes (Must be a resident for 30 days with intent to stay)	--
American Samoa	--	--	--	--	--
Arizona	300% GR	--	--	Yes (Proof required)	--
Arkansas	200% GR	Yes	--	Yes (Proof required)	--
California	400% GR	--	--	Yes (Proof required)	--
Colorado	400% GR	--	--	Yes (Proof required)	--
Connecticut	400% NET	--	--	Yes (Proof required)	--
Delaware	500% GR	Yes	Yes	Yes	--
District of Columbia	500% GR	--	Yes	Yes (Proof required)	--
Federated States of Micronesia	--	--	--	--	--
Florida	400% GR	Yes	--	Yes (Proof required)	--
Georgia	300% GR	Yes	Yes	Yes (Proof required)	--
Guam	200% NET	--	--	Yes (Must be a resident for 6 months prior to application)	Must be enrolled in case management services.
Hawaii	400% GR	--	--	Yes	Must be enrolled in case management services.
Idaho	200% GR	--	--	Yes	--
Illinois	400% GR	--	--	Yes	--
Indiana	300% GR	--	--	Yes	Must be enrolled in case management services.
Iowa	200% GR	--	Yes	Yes (Without an absence of more than two months)	--
Kansas	300% GR	--	--	Yes (Proof required)	--
Kentucky	300% GR	Yes	Yes	Yes (Proof required)	--
Louisiana	300% GR	--	Yes	Yes (Proof required)	--
Maine	500% GR	--	--	Yes (Proof required)	--
Marshall Islands	--	--	--	--	--
Maryland	500% GR	--	--	Yes (Proof required)	--
Massachusetts	500% GR	--	--	Yes (Proof required)	--
Michigan	450% GR	--	--	Yes	--
Minnesota	300% GR	--	Yes	Yes	--
Mississippi	--	--	--	Yes (Proof required)	--
Missouri	300% GR	--	--	Yes (Proof required)	--
Montana	330% GR	--	--	Yes (Proof required)	--
Nebraska	200% GR	--	--	Yes (Proof required)	--
Nevada	400% GR	--	Yes	Yes (Proof required)	--
New Hampshire	300% GR	Yes	--	Yes (Proof required)	--
New Jersey	500% GR	--	--	Yes (Must be a resident for 30 days with intent to stay)	--
New Mexico	400% GR	--	Yes	Yes (Proof required)	--
New York	406% GR	--	Yes	Yes	--
North Carolina	300% GR	Yes	--	Yes	--
North Dakota	400% NET	--	--	Yes (Proof required)	--
Northern Mariana Islands	--	--	--	--	--
Ohio	500% GR	--	--	Yes (Proof required)	--
Oklahoma	200% GR	--	--	Yes (Proof required)	--
Oregon <sup>3</sup>	200% GR	--	Yes	Yes (Proof required)	--
Pennsylvania	337% GR	--	--	Yes (Proof required)	--
Puerto Rico	200% NET	--	--	Yes (Must be a resident for 30 days)	--
Rhode Island	400% GR	--	--	--	--
South Carolina	300% GR	--	--	Yes	--
South Dakota	300% GR	--	--	Yes	--
Tennessee	300% GR	--	Yes	Yes (Proof required)	Must be enrolled in case management services.
Texas	200% GR	Yes	--	Yes	--
Utah	250% GR	--	Yes	Yes	--
Vermont	200% NET	--	--	Yes (Proof required)	--
Virgin Islands (U.S.)	400% GR	--	--	--	--
Virginia <sup>4</sup>	400% GR	--	--	Yes	--
Washington	300% GR	--	Yes	Yes (Proof required)	--
West Virginia	325% GR	--	--	Yes (Proof required)	--
Wisconsin	300% GR	--	--	Yes (Proof required)	--
Wyoming	332% GR	--	--	Yes (Proof required)	--
<b>Total</b>		<b>8</b>	<b>14</b>	<b>52</b>	<b>4</b>

<sup>1</sup> The 2009 Federal Poverty Level (FPL) was \$10,830 (slightly higher in Alaska and Hawaii) for a household of one. GR=Gross income; NET=Net income.

<sup>2</sup> CD4=CD4 cell count; VL = Viral load.

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. Following reauthorization of the Ryan White Program in 2006, the Republic of Palau was eligible for ADAP funding, but did not receive funding in FY2009 and is not included above. For all other ADAPs, a dash (-) indicates no requirement for the ADAP.

Table XVII  
ADAP Client Enrollment Processes, June 2009

State/Territory	Intake at Local ASOs, CBOs, and Local Health Department <sup>1</sup>	Intake at ADAP Office	Intake at Private Clinical Settings	Online Application	Application Over the Phone	Mailed Application	Enrollment via Other State Programs	Other Enrollment Processes
Alabama	--	Yes	Yes	Yes	Yes	Yes	--	Yes
Alaska	Yes	Yes	--	--	Yes	Yes	--	Yes
American Samoa	--	--	--	--	--	--	--	--
Arizona	Yes	Yes	Yes	--	--	Yes	--	Yes
Arkansas	Yes	--	--	--	--	--	--	--
California	Yes	--	--	--	--	--	--	--
Colorado	Yes	Yes	Yes	--	--	Yes	--	Yes
Connecticut	Yes	Yes	Yes	--	--	Yes	Yes	--
Delaware	Yes	--	--	--	--	--	--	--
District of Columbia	Yes	Yes	--	--	--	Yes	--	--
Federated States of Micronesia	--	--	--	--	--	--	--	--
Florida	Yes	Yes	--	--	--	--	--	--
Georgia	Yes	--	Yes	--	--	--	--	--
Guam	--	--	--	--	--	--	--	Yes
Hawaii	Yes	--	--	--	--	--	--	--
Idaho	Yes	--	--	--	--	--	--	--
Illinois	--	--	--	--	--	Yes	--	Yes
Indiana	Yes	--	--	--	--	--	--	--
Iowa	Yes	--	--	--	--	--	--	--
Kansas	Yes	Yes	--	--	--	--	--	--
Kentucky	Yes	--	--	--	--	--	--	--
Louisiana	Yes	Yes	Yes	--	--	Yes	--	Yes
Maine	Yes	--	Yes	--	--	Yes	--	--
Marshall Islands	--	--	--	--	--	--	--	--
Maryland	--	--	--	--	--	Yes	--	--
Massachusetts	Yes	Yes	Yes	--	--	Yes	--	--
Michigan	Yes	Yes	Yes	--	--	Yes	--	--
Minnesota	--	Yes	--	--	--	Yes	--	--
Mississippi	--	--	--	--	--	--	--	--
Missouri	Yes	--	--	--	--	--	--	--
Montana	Yes	--	--	--	--	Yes	--	--
Nebraska	Yes	Yes	Yes	--	--	Yes	--	--
Nevada	--	--	--	--	--	--	--	Yes
New Hampshire	--	--	--	--	--	--	--	--
New Jersey	Yes	Yes	Yes	--	--	Yes	--	--
New Mexico	--	--	--	--	--	--	--	Yes
New York	--	--	--	--	--	Yes	--	--
North Carolina	Yes	--	Yes	--	--	--	Yes	--
North Dakota	Yes	--	--	--	--	--	--	--
Northern Mariana Islands	--	--	--	--	--	--	--	--
Ohio	Yes	--	Yes	--	--	Yes	--	--
Oklahoma	--	--	--	--	--	--	--	Yes
Oregon	--	Yes	--	--	--	Yes	--	--
Pennsylvania	--	--	--	--	Yes	Yes	--	--
Puerto Rico	Yes	Yes	--	--	--	--	--	Yes
Rhode Island	Yes	--	Yes	--	--	Yes	Yes	--
South Carolina	Yes	--	Yes	--	--	--	--	--
South Dakota	--	Yes	Yes	--	--	Yes	Yes	Yes
Tennessee	Yes	--	Yes	--	--	--	--	--
Texas	--	--	--	--	--	Yes	--	Yes
Utah	--	--	Yes	--	--	Yes	--	--
Vermont	Yes	Yes	--	Yes	--	Yes	--	--
Virgin Islands (U.S.)	Yes	--	--	--	--	--	--	--
Virginia	Yes	--	--	--	--	--	--	Yes
Washington	--	--	--	--	--	Yes	--	Yes
West Virginia	Yes	Yes	Yes	--	--	Yes	Yes	Yes
Wisconsin	Yes	Yes	Yes	--	--	Yes	--	--
Wyoming	Yes	--	--	--	--	--	--	--
<b>Total</b>	<b>37</b>	<b>20</b>	<b>20</b>	<b>2</b>	<b>3</b>	<b>28</b>	<b>5</b>	<b>16</b>

<sup>1</sup> ASOs=AIDS Service Organizations; CBOs=Community-Based Organizations.

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. Following reauthorization of the Ryan White Program in 2006, the Republic of Palau was eligible for ADAP funding, but did not receive funding in FY2009 and is not included above.

Table XVIII

## ADAP Management Policies in Place, June 30, 2009

State/Territory	Client Cost-Sharing	Overall Program Enrollment Cap	Drug Specific Enrollment Cap	Maximum Cost Per Client	Maximum Number of Prescriptions Per Client Per Month
Alabama	--	--	--	--	--
Alaska	--	--	--	--	--
American Samoa	--	--	--	--	--
Arizona	--	--	--	--	--
Arkansas	--	--	--	--	--
California	Yes	--	--	--	--
Colorado	--	--	--	--	--
Connecticut	--	--	--	--	--
Delaware	Yes	--	--	--	--
District of Columbia	--	--	--	--	--
Federated States of Micronesia	--	--	--	--	--
Florida	--	--	--	--	--
Georgia	--	--	--	--	Yes (4 antiretrovirals and opportunistic infection medications per month)
Guam	--	--	--	--	--
Hawaii	--	--	--	--	--
Idaho	--	--	--	--	--
Illinois	--	--	Yes (Fuzeon)	Yes (\$2,000 per month)	Yes (5 antiretrovirals plus a reduced does of Norvir per month)
Indiana	--	Yes (1,470)	--	--	--
Iowa	--	--	--	--	--
Kansas	--	--	--	--	--
Kentucky	--	--	--	--	--
Louisiana	--	--	--	--	--
Maine	--	--	--	--	--
Marshall Islands	--	--	--	--	--
Maryland	Yes	--	--	--	--
Massachusetts	--	--	--	--	--
Michigan	--	--	--	--	--
Minnesota	--	--	--	--	--
Mississippi	--	--	--	--	--
Missouri	--	--	--	--	--
Montana	--	--	Yes (Fuzeon)	--	--
Nebraska	--	--	--	--	--
Nevada	--	--	--	--	--
New Hampshire	--	--	--	--	--
New Jersey	--	--	--	--	--
New Mexico	--	--	--	--	--
New York	--	--	--	--	--
North Carolina	--	--	--	--	--
North Dakota	--	--	--	--	--
Northern Mariana Islands	--	--	--	--	--
Ohio	--	--	--	--	--
Oklahoma	--	--	--	--	--
Oregon	Yes	--	--	--	--
Pennsylvania	--	--	--	--	--
Puerto Rico	--	--	--	--	--
Rhode Island	--	--	--	--	--
South Carolina	Yes	--	--	--	--
South Dakota	--	--	--	Yes (\$10,500 per year)	--
Tennessee	--	--	--	--	--
Texas	--	--	--	--	Yes (4 antiretrovirals per month)
Utah	--	--	--	--	--
Vermont	--	--	--	--	--
Virgin Islands (U.S.)	--	--	--	--	--
Virginia	--	--	--	--	--
Washington	Yes	--	--	--	--
West Virginia	--	--	Yes (Fuzeon)	--	--
Wisconsin	--	--	--	--	--
Wyoming	--	Yes (125)	--	--	--
<b>Total</b>	<b>6</b>	<b>2</b>	<b>3</b>	<b>2</b>	<b>3</b>

<sup>1</sup> Step therapy is the practice of beginning drug therapy for a medical condition with the most cost-effective and safest drug therapy and progressing to other more costly or risky therapy, only if necessary. The aims are to control costs and minimize risks. Also called step protocol. Step therapy does not apply to antiretrovirals.

Drug(s) with Clinical Criteria	Drug(s) with Prior Authorization	Drug(s) with Required Resistance Testing	Other ADAP Program Practices/Restrictions
Fuzeon, Maravac, Procrit	Fuzeon, Maravac, Procrit	Fuzeon, Selzentry	--
--	--	--	--
--	--	--	--
Maravac	Fuzeon, Pregablin	--	--
--	Fuzeon	--	--
Bupropion, Capreomycin, Caspofungin, Cycloserine, Dextroamphetamine, Ethionamide, Fentanyl patch, Imipenem, Lansoprazole, Linezolid, Maravac, Methadone, Methylphenidate, Moxifloxacin, Nandrolone, Omeprazole, Paclitaxel, Para-aminosalicylate, Serostim, Testosterone, Valacyclovir, Vanciclovir, Voriconazole	--	--	Step therapy
--	--	--	--
--	Serostim	--	--
--	--	--	--
--	Abacavir, Fuzeon, Selzentry	--	--
--	--	--	--
--	Fuzeon, Selzentry	Fuzeon, Selzentry	--
--	Fuzeon, Selzentry	Fuzeon, Selzentry	--
--	--	--	--
Fuzeon	Fuzeon	--	--
Selzentry	Fuzeon, Aptivus	--	--
--	Fuzeon, Oral valcyte	--	--
--	--	--	--
--	Fuzeon	--	--
Selzentry	Fuzeon	--	--
--	--	--	--
--	--	--	--
Selzentry	Androgel, Ferrous Sulfate, Lyrica, Nandrolone, Testosterone	--	--
--	--	--	--
--	Epoetin alpha, Enfurvitide, Figrastim, Peginterferon Alpha 2a and 2b, Oxandrolone	--	--
--	--	--	--
Selzentry, procrit, neupogen	Fuzeon, Neupogen, Procrit, Selzentry	Fuzeon, Selzentry	Step therapy for antidepressants, PPI, valtrex, intelence; daily dose limits
--	--	--	--
--	--	--	--
--	--	--	--
Fuzeon	Aptivus, Amphotercin B, Cancidas, Trizivir, Atripla, Epogen, Fuzeon, Intelence, Isentress, Neurontin, Prezista, Selzentry, Testosterone	Aptivus, Selzentry	--
--	Enfurvitide, Maravac, Raltegravir	--	--
--	--	--	--
--	--	--	--
All second line antiretrovirals	All second line antiretrovirals	All second line antiretrovirals	--
--	Amikin, Cytovene, Diflucan, Epogen, Famvir, Fuzeon, Isentress, Megace, Mepron, Neupogen, Prezista, Selzentry, Sporanax, Valcyte, Vfend	--	--
--	Aptivus, Atovaquone, Epogen, Fuzeon, G-csf, Mepron, Nuemega, Selzentry, Win Rho	Selzentry	--
--	Selzentry	Selzentry	--
--	--	--	--
--	--	--	--
Selzentry	Chantrix	Selzentry	--
--	--	--	--
--	--	--	--
--	--	--	--
Selzentry	Fuzeon, Selzentry	Fuzeon	--
--	Copegus, Fuzeon, Isentress, PEG-intron, Rebetol, Selzentry	--	--
--	Abacavir, Enfurvitide, Maravac, Peginterferon Alfa 2-a, Peginterferon Alfa 2-b, Ribavirin	--	--
--	Fuzeon	--	--
--	Fuzeon, Selzentry	Selzentry	--
Each drug has specific criteria; see program guidelines	--	Selzentry	--
--	--	--	--
--	Fuzeon, Selzentry, Valcyte	Fuzeon, Selzentry	--
--	--	--	--
Aptivus, Deltasone, Fuzeon, Intelence, Selzentry, Voriconazole	Enfurvitide, Etrvirine, Predinsone, Tipranavir, Voriconazole	--	--
Fuzeon, Aptivus, Maravac, Baraclude	Aptivus, Baraclude, Clarithromycin, Fosamprenavir, Fuzeon, Marinol, Maravac, Norvir, Valtrex, Zofran	Fuzeon	--
--	Foscavir, Fuzeon, Selzentry	Selzentry	--
--	--	--	--
--	Selzentry	--	--
15	32	15	2

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. Following reauthorization of the Ryan White Program in 2006, the Republic of Palau was eligible for ADAP funding, but did not receive funding in FY2009 and is not included above.

Table XIX  
ADAP Policies Related to Medicare Part D, June 2009

State/Territory	ADAP Pays Part D Premiums		ADAP Pays Part D Deductibles		ADAP Pays Part D Co-Payments				Not Eligible for ADAP <sup>1</sup>				Provide Medications During Coverage Gap <sup>3</sup>
	Partial Subsidy Clients	Standard Clients	Partial Subsidy Clients	Standard Clients	Dually Eligible Clients <sup>2</sup>	Full Subsidy Clients	Partial Subsidy Clients	Standard Clients	Dually Eligible Clients <sup>2</sup>	Full Subsidy Clients	Partial Subsidy Clients	Standard Clients	
Alabama	--	Yes	--	--	--	--	--	Yes	--	--	--	Yes	Yes
Alaska	--	--	Yes	Yes	--	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes
American Samoa	--	--	--	--	--	--	--	--	--	--	--	--	--
Arizona	--	--	--	--	--	--	Yes	Yes	Yes	--	--	--	Yes
Arkansas	--	--	Yes	Yes	--	--	Yes	Yes	--	--	Yes	Yes	--
California	--	--	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	--	Yes
Colorado	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	--	Yes
Connecticut	Yes	Yes	--	--	--	Yes	Yes	Yes	Yes	--	--	--	Yes
Delaware	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	--	Yes
District of Columbia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	--	Yes
Federated States of Micronesia	--	--	--	--	--	--	--	--	--	--	--	--	--
Florida	Yes	--	Yes	--	--	Yes	Yes	--	--	Yes	Yes	Yes	--
Georgia	Yes	Yes	--	--	3	--	Yes	Yes	--	--	Yes	Yes	Yes
Guam	--	--	--	--	--	--	--	--	Yes	Yes	Yes	Yes	--
Hawaii	--	--	Yes	Yes	--	--	Yes	Yes	Yes	Yes	--	--	--
Idaho	--	--	--	--	--	--	--	--	Yes	Yes	Yes	Yes	--
Illinois	--	--	--	--	--	--	--	--	Yes	Yes	Yes	Yes	--
Indiana	--	--	Yes	Yes	--	Yes	Yes	Yes	Yes	--	--	--	Yes
Iowa	Yes	Yes	Yes	Yes	--	--	Yes	Yes	Yes	Yes	--	--	Yes
Kansas	--	--	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	Yes	Yes
Kentucky	--	--	--	--	Yes	Yes	Yes	Yes	--	--	--	--	Yes
Louisiana	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	--	Yes
Maine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	--	Yes
Marshall Islands	--	--	--	--	--	--	--	--	--	--	--	--	--
Maryland	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	--	--	--	Yes
Massachusetts	--	Yes	--	--	Yes	--	--	Yes	--	--	--	--	Yes
Michigan	Yes	--	Yes	Yes	--	Yes	Yes	Yes	Yes	--	--	--	Yes
Minnesota	Yes	Yes	Yes	Yes	--	--	Yes	Yes	Yes	Yes	--	--	Yes
Mississippi	--	--	--	--	--	--	--	--	--	--	--	--	--
Missouri	--	--	--	--	--	--	--	--	--	--	--	--	Yes
Montana	--	--	--	--	--	--	--	--	Yes	Yes	Yes	Yes	--
Nebraska	Yes	Yes	--	--	--	Yes	Yes	Yes	Yes	--	--	--	--
Nevada	Yes	Yes	Yes	Yes	--	--	Yes	Yes	Yes	--	Yes	Yes	Yes
New Hampshire	--	--	--	--	--	--	--	--	--	--	--	--	--
New Jersey	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	--	--	--	Yes
New Mexico	--	--	--	--	--	--	--	--	--	--	--	--	--
New York	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	--	--	--	--	Yes
North Carolina	--	--	Yes	Yes	--	--	Yes	Yes	Yes	Yes	--	--	Yes
North Dakota	--	--	--	--	Yes	Yes	Yes	Yes	--	--	--	--	--
Northern Mariana Islands	--	--	--	--	--	--	--	--	--	--	--	--	--
Ohio	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes
Oklahoma	--	--	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	--	Yes
Oregon	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	--	Yes
Pennsylvania	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	--	Yes
Puerto Rico	--	--	--	--	--	--	--	--	Yes	--	--	--	--
Rhode Island	--	--	--	--	Yes	3	3	3	3	3	3	3	3
South Carolina	--	--	--	--	--	--	Yes	Yes	Yes	--	--	--	Yes
South Dakota	--	--	--	--	Yes	Yes	Yes	Yes	--	--	--	--	Yes
Tennessee	--	--	--	--	--	--	--	--	--	--	--	--	--
Texas	--	--	--	--	--	--	--	--	Yes	Yes	--	--	--
Utah	Yes	Yes	--	--	--	Yes	Yes	Yes	Yes	--	--	--	Yes
Vermont	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	--	Yes
Virgin Islands	--	--	--	--	--	--	--	--	--	--	--	--	--
Virginia	--	--	--	--	--	--	--	--	Yes	Yes	--	--	--
Washington	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	--	Yes
West Virginia	--	--	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	--	Yes
Wisconsin	--	Yes	--	Yes	--	--	--	Yes	Yes	Yes	Yes	--	Yes
Wyoming	--	--	--	--	--	--	--	--	--	--	--	--	--
<b>Total</b>	<b>22</b>	<b>23</b>	<b>27</b>	<b>27</b>	<b>19</b>	<b>27</b>	<b>36</b>	<b>38</b>	<b>23</b>	<b>14</b>	<b>11</b>	<b>11</b>	<b>35</b>

<sup>1</sup> Clients receiving any portion of the Medicare Part D subsidy were disenrolled from ADAP because the benefit provided them comprehensive care. In many instances, when standard clients were disenrolled from ADAP, they were consequently enrolled in other State Pharmacy Assistance Programs (SPAPs).

<sup>2</sup> Eligible for both Medicare and Medicaid.

<sup>3</sup> Once a client reaches the coverage gap (or "doughnut hole") in their Part D plan, the client will revert back to ADAP to receive all medications available through the ADAP formulary.

Table XX

## Number of People on ADAP Waiting Lists, by Survey Period, July 2002-March 2009

State/Territory	Jul-02	Oct-02	Dec-02	Jan-03	Feb-03	Mar-03	Apr-03	May-03	Jun-03	Aug-03	Sep-03	Nov-03	Jan-04	Mar-04	May-04	Jul-04
Alabama	250	175	175	175	175	175	104	104	90	89	107	141	247	304	395	353
Alaska										1			4	9	7	8
American Samoa																
Arizona																
Arkansas															3	
California																
Colorado									12	28	80	130	190	292	310	
Connecticut																
Delaware																
District of Columbia																
Federated States of Micronesia																
Florida																
Georgia																
Guam			4	4	4	4	4									
Hawaii																
Idaho													3	5	13	24
Illinois																
Indiana	30	34	34	34	34	34				47	48	47				
Iowa															6	31
Kansas																
Kentucky	50	62	121	121	121	121	141	141	130	135	165	140	140	123	113	138
Louisiana																
Maine																
Marshall Islands																
Maryland																
Massachusetts																
Michigan																
Minnesota																
Mississippi																
Missouri																
Montana	2	2	8	8	8						4	1	4	4	8	10
Nebraska			8	8	15	15	29	29	30	36	30	30				
Nevada																
New Hampshire																
New Jersey																
New Mexico																
New York																
North Carolina	715	776	150	150	217		50					96	126	449	716	891
North Dakota																
Northern Mariana Islands																
Ohio																
Oklahoma																
Oregon	18	18	9	9	9	145	236	236	220	228	228	24				
Pennsylvania																
Puerto Rico																
Rhode Island																
South Carolina																
South Dakota	43	43	43	43	43	43	49	49	49	52	50		49	43	23	28
Tennessee																
Texas																
Utah																
Vermont																
Virgin Islands (U.S.)																
Virginia																
Washington																
West Virginia							9	9	10	12	14	21	28	34	35	35
Wisconsin																
Wyoming																
<b>Total # People on Waiting Lists</b>	<b>1108</b>	<b>1110</b>	<b>552</b>	<b>552</b>	<b>626</b>	<b>537</b>	<b>622</b>	<b>568</b>	<b>541</b>	<b>628</b>	<b>726</b>	<b>630</b>	<b>791</b>	<b>1263</b>	<b>1629</b>	<b>1518</b>
<b>Total # of States with Waiting Lists</b>	<b>7</b>	<b>7</b>	<b>9</b>	<b>9</b>	<b>9</b>	<b>7</b>	<b>8</b>	<b>6</b>	<b>7</b>	<b>9</b>	<b>9</b>	<b>9</b>	<b>9</b>	<b>9</b>	<b>11</b>	<b>9</b>

(continued on next page)

Table XX (continued from previous page)

## Number of People on ADAP Waiting Lists, by Survey Period, July 2002-March 2009

State/Territory	Sep-04	Nov-04	Jan-05	Mar-05	May-05	Jul-05	Sep-05	Nov-05	Jan-06	Feb-06	May-06	Jul-06	Sep-06	Nov-06	Jan-07
Alabama	393	244	126	133	180	143	168	196	285	280	38		6		
Alaska	12	4	5	1			8	8	12	12			10	10	16
American Samoa															
Arizona															
Arkansas	11	31	30	43	59	55	78	73	89	89	21	4			
California															
Colorado															
Connecticut															
Delaware															
District of Columbia															
Federated States of Micronesia															
Florida															
Georgia															
Guam															
Hawaii		7													
Idaho	34		1	5	13	18	26	33	40	36	15				
Illinois															
Indiana									9	9	8		33		
Iowa	46	12	39	47	55										
Kansas															
Kentucky	191		27	72	80	125	192	217	258	211	188	153			
Louisiana															
Maine															
Marshall Islands															
Maryland															
Massachusetts															
Michigan															
Minnesota															
Mississippi															
Missouri															
Montana	14		6	5	4	6	15	12	17	17	20	20	20	22	22
Nebraska		15	27	46	61	85	85	92	89	94					
Nevada															
New Hampshire															
New Jersey															
New Mexico															
New York															
North Carolina	524	493	325	325		2	293	13	83						
North Dakota															
Northern Mariana Islands															
Ohio															
Oklahoma															
Oregon															
Pennsylvania															
Puerto Rico															126
Rhode Island															
South Carolina												94	209	308	394
South Dakota	36														
Tennessee															
Texas															
Utah	11														
Vermont															
Virgin Islands (U.S.)															
Virginia															
Washington															
West Virginia	35	5	1	1	1	1	1	3	43	43	41	39	24		
Wisconsin															
Wyoming		2	5	6											
<b>Total # People on Waiting Lists</b>	<b>1307</b>	<b>813</b>	<b>592</b>	<b>684</b>	<b>453</b>	<b>435</b>	<b>866</b>	<b>647</b>	<b>925</b>	<b>791</b>	<b>331</b>	<b>310</b>	<b>302</b>	<b>340</b>	<b>558</b>
<b>Total # of States with Waiting Lists</b>	<b>11</b>	<b>9</b>	<b>11</b>	<b>11</b>	<b>9</b>	<b>9</b>	<b>9</b>	<b>9</b>	<b>10</b>	<b>9</b>	<b>7</b>	<b>5</b>	<b>6</b>	<b>3</b>	<b>4</b>

	Mar-07	May-07	Jul-07	Sep-07	Jan-08	Mar-08	Jul-08	Oct-08	Jan-09	Mar-09	May-09	Aug-09	Nov-09	Mar-10	# of Periods w/ Waiting Lists	Average # of People on Waiting List
															28	188
	13	1	5												21	8
													9	18	15	41
															7	149
															5	4
															1	7
														17	15	19
							28	32	8	16	26				18	28
												7	27	55	10	33
												50	128	172	30	134
	20	22			1	3	7	16	19	19	19	24	18	14	37	12
								5	16	27	51	70	30		25	41
														168	20	328
															12	115
	75	36													3	79
	463	470	303												7	320
															19	38
												1	14	26	2	126
													142	110		
													37	69	3	39
															23	19
											3	5	13	13	7	7
	571	529	308	0	1	3	35	53	43	62	99	157	418	662		571
	4	4	2	0	1	1	2	3	3	3	4	6	9	10	329	

Table XXI  
ADAP Formulary Coverage, December 31, 2009

State/Territory	Total Number of Drugs on Formulary	NRTIs Covered (11 Drugs Approved) <sup>1</sup>	NNRTIs Covered (4 Drugs Approved) <sup>2</sup>	Protease Inhibitors Covered (10 Drugs Approved) <sup>3</sup>	Fusion Inhibitors Covered (1 Drug Approved)	CCR5 Antagonists Covered (1 Drug Approved)	Integrase Inhibitors Covered (1 Drug Approved)	Multi-Class Combination Products Covered (1 Drug Approved) <sup>4</sup>	"A1" OI Covered (31 DHHS Recommended Drugs) <sup>5</sup>	Other Medications Covered <sup>6</sup>
Alabama	52	11	3	10	1	1	1	1	21	3
Alaska	83	11	4	10	1	1	1	1	28	26
American Samoa	--	--	--	--	--	--	--	--	--	--
Arizona	160	11	4	9	1	1	1	1	11	121
Arkansas	91	11	3	9	1	1	1	1	12	52
California	176	11	4	10	1	1	1	1	25	122
Colorado	98	11	4	9	1	1	1	1	18	52
Connecticut	189	11	4	10	1	1	1	1	16	144
Delaware	253	11	4	10	1	1	1	1	24	200
District of Columbia	86	11	4	9	1	1	1	1	19	39
Federated States of Micronesia	--	--	--	--	--	--	--	--	--	--
Florida	95	11	4	10	1	1	1	1	14	52
Georgia	59	11	4	10	1	1	1	1	17	13
Guam	41	11	4	10	1	1	1	1	12	--
Hawaii	114	11	4	10	1	1	1	1	27	58
Idaho	28	11	3	7	1	1	1	1	3	0
Illinois	99	11	4	10	1	1	1	1	31	39
Indiana	135	11	4	10	1	1	1	1	24	82
Iowa	67	11	4	9	1	1	1	1	21	18
Kansas	56	11	4	10	1	1	1	1	8	19
Kentucky	63	11	3	10	1	1	1	1	14	21
Louisiana	60	11	4	10	1	1	1	1	28	3
Maine	328	11	4	10	1	1	1	1	31	268
Marshall Islands	--	--	--	--	--	--	--	--	--	--
Maryland	153	11	4	9	1	1	1	1	22	103
Massachusetts	Open formulary	11	4	10	1	1	1	1	31	Open formulary
Michigan	183	11	4	10	1	1	1	1	23	131
Minnesota	134	11	4	9	1	1	1	1	14	92
Mississippi	66	11	3	10	1	1	1	1	28	10
Missouri	238	11	4	10	1	1	1	1	21	188
Montana	69	11	4	9	1	1	1	1	19	22
Nebraska	123	11	4	9	1	1	1	1	15	80
Nevada	77	11	4	9	1	1	1	1	12	37
New Hampshire	Open formulary	11	4	10	1	1	1	1	31	Open formulary
New Jersey	Open formulary	11	4	10	1	1	1	1	31	Open formulary
New Mexico	71	11	4	9	1	1	1	1	13	30
New York	465	11	4	10	1	1	1	1	27	409
North Carolina	124	11	4	10	1	1	1	1	19	76
North Dakota	94	11	4	8	1	1	1	1	19	48
Northern Mariana Islands	--	--	--	--	--	--	--	--	--	--
Ohio	104	11	4	10	1	1	1	1	11	64
Oklahoma	47	10	4	9	1	1	1	1	13	7
Oregon	97	11	4	10	1	1	1	1	21	47
Pennsylvania	89	11	4	10	1	1	1	1	27	38
Puerto Rico	68	11	4	9	1	1	1	1	19	21
Rhode Island	68	11	3	10	1	1	1	1	16	24
South Carolina	63	11	4	10	1	1	1	1	19	15
South Dakota	58	11	4	10	1	1	1	1	12	17
Tennessee	70	11	3	9	1	1	1	1	14	29
Texas	44	11	4	9	1	1	1	1	9	7
Utah	81	11	4	10	1	1	1	1	14	38
Vermont	83	11	4	9	1	1	1	1	16	39
Virgin Islands (U.S.)	63	11	4	10	1	1	1	1	31	3
Virginia	94	11	4	9	1	1	1	1	21	45
Washington	162	11	4	10	1	1	1	1	23	110
West Virginia	68	11	4	9	1	1	1	1	15	25
Wisconsin	66	11	4	10	1	1	1	1	20	17
Wyoming	108	11	4	10	1	1	1	1	28	51

<sup>1</sup> NRTI=Nucleoside Reverse Transcriptase Inhibitor.

<sup>2</sup> NNRTI=Non-Nucleoside Reverse Transcriptase Inhibitor.

<sup>3</sup> Fortovase (saquinavir soft-gel) is no longer marketed by the manufacturer. The *National ADAP Monitoring Project Annual Report* counts Fortovase and Invirase (saquinavir hard-gel) as one drug for the purposes of tabulating the number of protease inhibitors covered on an ADAP's formulary.

<sup>4</sup> Atripla is a multi-class combination product that includes efavirenz (NNRTI), emtricitabine (NRTI), and tenofovir disoproxil fumarate (NRTI). In addition, the multi-class combination products listed above are not considered a class of drugs since their component parts are included in other drug classes, and are therefore not required to be included in ADAP formularies.

<sup>5</sup> DHHS=Department of Health and Human Services; "A1 OI"=Drugs recommended ("A1") for the prevention and treatment of opportunistic infections (OIs).

<sup>6</sup> Examples of "Other Medications" include those used to treat depression, hypertension, and diabetes.

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not report data. Following reauthorization of the Ryan White Program in 2006, the Republic of Palau was eligible for ADAP funding, but did not receive funding in FY2009 and is not included above. The reauthorization of the Ryan White Program in 2006 required ADAPs to cover at least one currently approved drug in each antiretroviral class beginning in July 2007.

Table XXII  
HIV/AIDS Medications

FDA-Approved Antiretroviral Medications	
GENERIC NAME	BRAND NAME
<b>Multi-Class Combination Products</b>	
efavirenz, emtricitabine, and tenofovir disoproxil fumarate	Atripla
<b>NRTIs</b>	
abacavir sulfate, ABC	Ziagen
abacavir, zidovudine, and lamivudine	Trizivir
abacavir and lamivudine	Epzicom
didanosine, dideoxyinosine, ddL	Videx
emtricitabine, FTC	Emtriva
lamivudine and zidovudine	Combivir
lamivudine, 3TC	Epivir
stavudine, d4T	Zerit
tenofovir, disoproxil fumarate, TDF	Viread
tenofovir disoproxil fumarate and emtricitabine	Truvada
zalcitabine, dideoxycytidine, ddC	Hivid <sup>1</sup>
zidovudine, azidothymidine, AZT, ZDV	Retrovir
<b>NNRTIs</b>	
delavirdine, DLV	Rescriptor
efavirenz, EFV	Sustiva
etravirine	Intelence
nnevirapine, NVP	Viramune
<b>Protease Inhibitors</b>	
amprenavir, APV	Agenerase <sup>2</sup>
atazanavir sulfate, ATV	Reyataz
darunavir	Prezista
fosamprenavir calcium, FOS-APV	Lexiva
indinavir, IDV	Crixivan
lopinavir and ritonavir, LPV/RTV	Kaletra
nelfinavir mesylate, NFV	Viracept
ritonavir, RTV	Norvir
saquinavir	Fortovase <sup>3</sup>
saquinavir mesylate, SQV	Invirase
tipranavir, TPV	Aptivus
<b>Fusion Inhibitors</b>	
enfuvirtide, T-20	Fuzeon
<b>Entry Inhibitors - CCR5 Co-Receptor Antagonist</b>	
maraviroc	Selzentry
<b>HIV Integrase Strand Transfer Inhibitors</b>	
raltegravir	Isentress

<sup>1</sup> The sale and distribution of Hivid (zalcitabine, dideoxycytidine, ddC) was discontinued as of December 2006.

<sup>2</sup> The manufacturer of Agenerase (amprenavir) discontinued the sale and distribution of the drug in capsule form, used for adult dosing, after 2004 and is instead manufacturing fosamprenavir (Lexiva), a "prodrug" of Agenerase (a prodrug is an inactive precursor of a drug, converted into its active form in the body). Agenerase is still available in pediatric dosing.

<sup>3</sup> Fortovase (saquinavir soft-gel) is no longer marketed.

Source: FDA, "Drugs Used in the Treatment of HIV Infection": <http://www.fda.gov/oashi/aids/virals.html>. Also see: DHHS, "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents," November 24, 2008: <http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7&ClassID=1>.

"A1" Medications for the Prevention & Treatment of Opportunistic Infections (Highly Recommended) <sup>1</sup>	
GENERIC NAME	BRAND NAME
acyclovir	Zovirax
amphotericin B	Fungizone
azithromycin	Zithromax
cidofovir	Vistide
clarithromycin	Biaxin
clindamycin	Cleocin
ethambutol	--
famciclovir	Famvir
fluconazole	Diflucan
flucytosine	Ancobon
foscarnet	Foscavir
ganciclovir	Cytovene
isoniazid (INH)	Lanizid, Nydravid
itraconazole	Sporonox
leucovorin calcium	Wellcovorin
liposomal amphotericin B	--
peg-interferon alfa-2a	PEG-Intron
peg-interferon alfa-2b	--
pentamidine	Nebupent
prednisone	Deltasone, Liquid Pred, Metocorten, Orasone, Panasol, Prednicen-M, Sterapred
probenecid	--
pyrazinamide (PZA)	--
pyrimethamine	Daraprim, Fansidar
ribavirin	Virazole, Rebetol, Copegus
rifabutin	Mycobutin
rifampin (RIF)	Rifadin, Rimactane
sulfadiazine (oral generic)	Microsulfon
trimethoprim- sulfamethoxazole (TMP/SMX)	Bactrim, Septra
valacyclovir	Valtrex
valganciclovir	Valcyte

<sup>1</sup> "A" = "should always be offered"; "1" = "evidence from at least one properly randomized, controlled trial"

Sources: CDC, "Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus." *MMWR*, 51 (No. RR08),1-46; 2002; CDC, "Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents." *MMWR*, 53 (No. RR15), 1-112; 2004. Also see: DHHS, "Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents," November 24, 2008: <http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=211&ClassID=4>.

Table XXIII

## Patient Assistance Program Eligibility by Company, April 2010

Company Name	Antiretrovial	Contact Information
ABBOTT VIROLOGY	Kaletra (lopinavir - ritonavir) Norvir (ritonavir)	1-800-222-6885 www.abbottpatientassistancefoundation.org
BOEHRINGER INGELHEIM	Aptivus (tipranavir) Viramune (nevirapine)	1-800-556-8317 www.boehringer-ingelheim.com
BRISTOL-MYERS SQUIBB VIROLOGY	Reyataz (atazanavir) Sustiva (efavirenz) Zerit (stavudine/ d4T)	1-888-281-8981 www.bms.com
BRISTOL-MYERS SQUIBB / GILEAD	Atripla (efavirenz - emtricitabine - tenofovir)	1-866-290-4767
GENENTECH (Roche)	Invirase (saquinavir) Fuzeon (enfuvirtide)	1-866-247-5084 www.rocheusa.com
GILEAD SCIENCES, INC.	Truvada (emtricitabine - tenofovir) Emtriva (emtricitabine/ FTC) Viread (tenofovir)	1-800-226-2056 www.gilead.com
MERCK & CO., INC.	Isentress (raltegravir) Crixivan (indinavir)	1-800-850-3430 www.isentress.com
TIBOTEC THERAPEUTICS	Prezista (darunavir) Intelence (etravirine)	1-800-652-6227 www.tibotectherapeutics.com
ViiV (GlaxoSmithKline and Pfizer)	Combivir (lamivudine - zidovudine) Epzicom (abacavir - lamivudine) Epivir (lamivudine/ 3TC) Retrovir (zidovudine/ AZT) Trizivir (abacavir - lamivudine - zidovudine) Ziagen (abacavir) Lexiva (fosamprenavir)	www.mysupportcard.com

## Glossary



**340B Drug Discount Program** – The federal 340B Drug Discount Program, authorized under the Veterans Health Care Act of 1992, enables ADAPs to purchase drugs at or below the statutorily defined 340B ceiling price.

**AIDS Drug Assistance Program (ADAP)** - A state administered program authorized under Part B (formerly Title II) of the Title XXVI of the Public Health Service Act as amended by the Ryan White HIV/AIDS Treatment Modernization Act of 2009 (Ryan White Program) that provides Food and Drug Administration (FDA) approved medications to low-income individuals with HIV disease who have limited or no coverage from private insurance or Medicaid. ADAPs may also purchase insurance and provide adherence monitoring and outreach under the flexibility policy.

**ADAP Crisis Task Force** – A group of state ADAP and AIDS directors, convened by NASTAD, that negotiates with the manufacturers of HIV antiretrovirals and other high-cost medications to secure supplemental discounts/rebates benefitting all ADAPs.

**ADAP Earmark** - The amount of federal Ryan White Program, Part B dollars specifically designated by Congress through the annual appropriations process to ADAP for the federal fiscal year.

**ADAP Supplemental Drug Treatment Grant** – ADAP Supplemental grants are used for the purchase of medications by states and territories with demonstrated severe need to increase access to HIV/AIDS related medications. These grants must be used to expand ADAP formularies, target resources to reflect the changes in the epidemic, and enhance the ADAP's ability to remove eligibility restrictions. States must meet HRSA eligibility criteria in order to apply for ADAP Supplemental funds. The overall supplemental amount is mandated by law to be five percent of the congressionally appropriated ADAP earmark, although it represented less than this in the overall ADAP budget.

**Back Billing** – In some instances, ADAP covers an individual's prescription costs but later determines there is another payer source, for example, state Medicaid. Once it is certain that another payer should have covered a client's previous claims, the ADAP can request reimbursement for expenditures previously incurred or "back bill." Another scenario for back billing is when individuals apply and are eligible for Medicaid. Their eligibility coverage back dates three months PRIOR to the application date. ADAP covers the individual while they wait for their Medicaid eligibility determination and then "back-bills" Medicaid for any drugs or services they paid for during the interim wait time (see also pay and chase).

**Co-Payment** - A cost-effective way to help clients access medications through existing insurance coverage. In those states where ADAPs largely use their funding to purchase or maintain health insurance coverage, co-payments accounted for a much greater share of expenditures. A set amount an individual must pay upon receiving medical services or prescriptions. For example, there may be a \$10 co-payment required each time a prescription is purchased at a retail pharmacy. Some ADAPs will pay the co-payments for ADAP formulary drugs.

**Cost recovery** - Reimbursement from third party entities such as private insurers and Medicaid.

**Cost-sharing** – The payment of a premium or fee by an enrolled ADAP client to the ADAP as a portion of the cost for medications and/or services received.

**Deductible** - The amount a health insurance beneficiary must pay before a third party payer begins to provide coverage for health services. Amounts can change from year to year. Some ADAPs pay this cost for eligible clients.

**Direct Purchase states** – ADAPs using this model centrally purchase and dispense medications through their own pharmacy or a single contract pharmacy services provider.

**Dual-Eligible** – Individuals who are eligible for both Medicare and Medicaid.

**Formulary** - ADAP drug list that establishes the number of drugs available within a therapeutic class for purposes of drug purchasing, dispensing and/or reimbursement. Effective July 1, 2007, all ADAPs were required to include at least one drug from each antiretroviral drug class. The minimum formulary requirement does not apply to multi-class combination products (not considered a unique class of drugs), drugs for preventing and treating opportunistic infections (OIs), hepatitis C treatments, or drugs for other HIV-related conditions (e.g., depression, hypertension, and diabetes).

- **Closed/restricted formulary** – allows only those drug products listed to be dispensed or reimbursed.
- **Open formulary** – covers all FDA-approved drugs prescribed by a physician with no restrictions or with restrictions such as higher patient cost-sharing requirements for certain drugs.
- **Tiered formulary** – also referred to as "step therapy" and is a cost containment measure that categorizes medications for a particular condition based upon their cost. For example, a tier one medication would be one that is lowest cost and recommended to be

used first, unless there are medical restrictions for doing so. Tier two would be a different medication that is prescribed for the same condition as the tier one drug but is more expensive. Step therapy or tiered formularies are most commonly used by ADAPs with medications prescribed for depression, respiratory problems, and opportunistic infections.

**Hybrid states** - A direct purchase state that utilizes an existing entity (e.g., University Hospital) to purchase and distribute ADAP drugs. The entity maintains a single drug inventory purchased at 340B prices. To secure the additional supplemental discounts negotiated by the ADAP Crisis Task Force, these ADAPs must submit rebate claims for any supplemental discount amounts.

**Insurance Continuation** - The payment of all or some combination of insurance premiums, co-pays, or deductibles for clients who have existing insurance policies through their current employment, Consolidated Omnibus Budget Reconciliation Act (COBRA) or other supplemental programs. HRSA allows ADAP funds to be used for insurance continuation with certain restrictions.

**Insurance Purchasing** - The purchase of new insurance policies through the insurance industry market or state high risk insurance pools.

**Part A funding** - Provided to metropolitan jurisdictions, similarly reflecting local decisions about whether to allocate funds to ADAPs.

**Part B "base"** - Formula-based funding to states (other than that earmarked for ADAP); some states choose to allocate some of this funding to ADAPs, but are not required to do so.

**Part B "base" supplemental funding** - Some states choose to allocate some of this funding to ADAPs, but are not required to do so.

**Patient Assistance Programs (PAPs)** - Programs through which many pharmaceutical manufacturers provide free or greatly subsidized medications to indigent patients.

**Rebate states** - These are ADAPs who pay retail pharmacies a pre-determined amount at the point of sale for drugs dispensed to ADAP clients. ADAP then bills drug manufacturers for the 340B Unit Rebate amount for the number of units dispensed.

**The Ryan White HIV/AIDS Treatment Modernization Act of 2009** - The Ryan White CARE Act, "Title XXVI of the PHS Act as amended by the Ryan White HIV/AIDS Treatment Modernization Act of 2009", or "Ryan White Program" is the single largest federal program designed specifically for people with HIV/AIDS. First enacted

in 1990, it provides care and treatment to individuals and families affected by HIV/AIDS. The Ryan White Program has five parts - **Part A** (formerly Title I) funds eligible metropolitan areas and transitional grant areas, 75 percent of grant funds must be spent for core services; **Part B** (formerly Title II) funds States/Territories, 75 percent must be spent for core services; **Part C** (formerly Title III) funds early intervention services, 75 percent must be spent for core services; **Part D** (formerly Title IV) grants support services for women, infants, children & youth and **Part F** comprises Special Projects of National Significance, AIDS Education & Training Centers (AETCs), Dental Programs and the Minority AIDS Initiative.

**State funding** - General revenue support from state budgets. States are not required to provide funding to their ADAPs (except in limited cases of matching requirements), although many have historically done so either over a sustained period of time or at critical junctures to address gaps in funding. Such funding is, for the most part, dependent on individual state decisions and budgets; even where states are required to provide a match of federal Part B Ryan White funds, they are not required to put this funding toward ADAP. The only exception to this is the ADAP supplemental, where states must provide a match (or seek a waiver of the requirement, if eligible to do so).

**True Out of Pocket Expenditures (TrOOP)** - This is the amount of money that a Medicare Part D enrolled client will have to pay from their own money to reach the "catastrophic limit" making Part D the primary payer for medications. Payments for drugs, co-payments, and coinsurance made by the beneficiary, friends, family members, State Pharmacy Assistance Programs, charities, and the Medicare low-income subsidy (LIS) count towards TrOOP costs. Payments for premiums, drugs not on plan formularies, costs incurred by the ADAP, and payments by other types of insurance are not counted as TrOOP costs.

## References



## References

- 1 ADAP fiscal years begin April 1 and end March 31.
- 2 [http://www.nastad.org/Docs/highlight/2010417\\_ADAP%20Crisis%20Strategy%20-%20FINAL.pdf](http://www.nastad.org/Docs/highlight/2010417_ADAP%20Crisis%20Strategy%20-%20FINAL.pdf)
- 1 For purposes of determining the overall ADAP budget, federal, state, and drug rebate funds are counted.
- 2 This estimate is based on annualizing June 2009 per capita drug expenditures. It is important to note that June 2009 expenditures may not be representative of monthly expenditures overall.
- 3 U.S. Food and Drug Administration, "Drugs Used in the Treatment of HIV Infection." Available at: <http://www.fda.gov/oashi/aids/virals.html>.
- 4 Centers for Disease Control and Prevention, "Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus." *MMWR* 2002; 51(RR08): 1-46. Available at: <http://www.aidsinfo.nih.gov/>.
- 5 Centers for Disease Control and Prevention, "Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents." *MMWR* 2004; 53(RR15): 1-112. Available at: <http://www.aidsinfo.nih.gov/>.
- 6 Centers for Disease Control and Prevention, "Sexually Transmitted Diseases Treatment Guidelines, 2006." *MMWR*, Vol. 55, September 2006.
- 7 Centers for Disease Control and Prevention, "Frequently Asked Questions and Answers About Coinfection with HIV and Hepatitis C Virus." Available at [http://www.cdc.gov/hiv/resources/qa/HIV-HCV\\_Coinfection.htm](http://www.cdc.gov/hiv/resources/qa/HIV-HCV_Coinfection.htm) (accessed March 10, 2009).
- 8 Health Resources and Services Administration, HIV/AIDS Bureau, Policy Notice 99-01, "The Use of the Ryan White CARE Act Title II ADAP Funds to Purchase Health Insurance."
- 9 Health Resources and Services Administration, HIV/AIDS Bureau, DSS Program Policy Guidance No. 2, "Allowable Uses of Funds for Discretely Defined Categories of Services," Formerly Policy No. 97-02, First Issued: February 1, 1997, June 1, 2000.
- 10 The 17 states with SPAPS are: Colorado, Connecticut, Hawaii, Idaho, Illinois, Maryland, Missouri, Montana, Nevada, New Jersey, New York, North Carolina, Pennsylvania, Texas, Vermont, Virginia, and Washington.

## Methodology

Since 1996, the National ADAP Monitoring Project has surveyed all jurisdictions receiving federal ADAP earmark funding through Ryan White. In FY2008, 58 jurisdictions received earmark funding and all 58 were surveyed; 53 responded. American Samoa, Federated States of Micronesia, Marshall Islands, Mississippi, and Northern Mariana Islands did not respond; these jurisdictions represent less than one percent of estimated living HIV and AIDS cases.\*

The annual survey requests data and other program information for a one-month period (June), the current fiscal year, and for other periods as specified. After the survey is distributed, NASTAD conducts extensive follow-up to ensure completion by as many ADAPs as possible. Data used in this report are from June 2009 and FY2009, unless otherwise noted.

All data reflect the status of ADAPs as reported by survey respondents; however, it is important to note that some program information may have changed between data collection and this report's release. Due to differences in data collection and availability across ADAPs, some are not able to respond to all survey questions. Where trend data are presented, only states that provided data in relevant periods are included. In some cases, ADAPs have provided revised program data from prior years and these revised data are incorporated where possible. Therefore, data from prior year reports may not be comparable for assessing trends. It is also important to note that data from a one-month snapshot may be subject to one-time only events or changes that could in turn appear to impact trends; these are noted where information is available. Data issues specific to a particular jurisdiction are provided on relevant charts and tables.



The National Alliance of State and Territorial AIDS Directors  
444 North Capitol Street, NW, Suite 339, Washington, DC 20001  
Phone 202.434.8090 Fax: 202.434.8092 [www.NASTAD.org](http://www.NASTAD.org)